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HCHWA-D Hereditary cerebral hemorrhage with amyloidosis, Dutch
HCHWA-I Hereditary cerebral hemorrhage with amyloidosis, 
Icelandic
HT Hypertension
IHC Immunohistochemistry
LCA Leukocyte common antigen (CD45)
LPL Lipoprotein lipase
LRP Low-density lipoprotein receptor-related protein
MI Myocardial infarction
MRI Magnetic resonance imaging
MUP Motor unit potential
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PCR Polymerase chain reaction
PNP Polyneuropathy
PP Precursor Protein
PS Presenilin
RAGE Receptor for advanced glycation end-products
RNA Ribonucleic acid
QST Quantitative sensory testing
SAP Serum amyloid P-component
SEP Sensory evoked potential
SMI311 A pan-neurophilament antibody cocktail
SNP Single nucleotide polymorphism
SSA Senile systemic amyloidosis
TTR Transthyretin
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ABSTRACT
This purpose of this study was to investigate the frequency, genetic- and 
health-associated risk factors, mutual association, and amyloid proteins 
in three old age-associated amyloid disorders: senile systemic amyloidosis 
(SSA), cerebral amyloid angiopathy (CAA), and hereditary gelsolin (AGel) 
amyloidosis. The study was part of the prospective population-based Vantaa 
85+ autopsy study on a Finnish population aged 85 years or more (n = 601) 
and was completed with a case report on a single patient with advanced 
AGel amyloidosis. 
The diagnosis and grading of amyloid were based upon histological 
examination of tissue samples obtained post mortem and stained with 
Congo red. The amyloid fibril and associated proteins were characterized 
by immunohistochemical staining methods. The genotype frequencies of 
candidate gene polymorphisms and information on health-associated risk 
factors in subjects with and without SSA and CAA were compared.
In a Finnish population ≥ 95 years of age, SSA and CAA occurred in 
36% and 49% of the subjects, respectively. In total, two-thirds of these very 
elderly individuals had SSA, CAA, or both, however these two conditions 
co-occurred in only 14% of the population. In subjects 85 years or older, 
the prevalence of SSA was 25%. In this population, SSA was associated with 
age at the time of death (p=0.002), myocardial infarctions (MIs; p=0.004), 
the G/G (Val/Val) genotype of the exon 24 polymorphism in the alpha2-
macroglobulin (α2M) gene (p=0.042), and with the H2 haplotype of the tau 
gene (p=0.016). In contrast, the presence of CAA was strongly associated 
with APOE ε4 (p=0.0003) and neuropathological AD (p=0.0005), and with 
clinical dementia (p=0.01) in both ε4+ (p=0.02) and ε4- (p=0.06) individuals. 
Apart from demonstrating the amyloid fibril proteins, complement proteins 
3d (C3d) and 9 (C9) were detected in the amyloid deposits of CAA and 
AGel amyloidosis, and α2M protein was found in fibrotic scar tissue close 
to SSA.
In conclusion, the study shows that while SSA and CAA do not associate 
with each other, the occurrence of one or both of them is extremely 
common in elderly individuals. Old age, MIs, the exon 24 polymorphism 
of the α2M gene, and H1/H2 polymorphism of the tau gene associate with 
SSA, .while clinical dementia and APOE ε4 genotype associate with CAA. 
The high prevalence of CAA, combined with its association with clinical 
dementia independent of APOE genotype, neuropathological AD, or SSA, 
also highlights its clinical significance in very elderly individuals, in whom 
the serious end stage complications of CAA, namely multiple infarctions 
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and hemorrhages, are rare. Further studies are warranted to confirm the 
findings in other populations and to clarify the role of α2M and tau in the 
pathogenesis of SSA. Importantly, the role of complement in amyloidosis 
should be further investigated, in particular its involvement in the process 
of amyloid beta (Aβ) protein elimination from the brain. Finally, the high 
prevalence of SSA in the elderly raises the need for prospective clinical 
studies to define its clinical significance.
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INTRODUCTION
Along with the increased life span of individuals (http://www.un.org/esa/
socdev/ageing/agewpop.httm), the burden of old age-associated diseases has 
inevitably increased (Jagger et al., 2007). Alzheimer’s disease (AD), probably 
the most well-known geriatric disease, belongs to the old age-associated 
amyloid diseases. While AD affects millions of elderly individuals in the 
Western countries (Gorshow, 2007) and is included as one of the leading 
causes of death (Heron and Smith, 2007), other representatives such as 
cerebral amyloid angiopathy (CAA) and senile systemic amyloidosis (SSA) 
have attained much less medical, and public, attention.
The term “amyloid” refers to the precipitation of protein in tissue, mainly 
as extracellular depositions of protein fibrils and with a characteristic 
appearance in electron microscopy, a typical X-ray diffraction pattern, and 
an affinity for Congo red with concomitant green birefringence (Westermark 
et al., 2005). Virchow introduced (Virchow, 1854a,b), the term “amyloid” to 
the medical literature in 1854 to describe cerebral cortical red homogenous 
material, and since then knowledge about amyloid composition has 
accumulated and a long list of amyloid diseases are now recognized. This 
study presents pathological, epidemiological, and genetic data for three 
forms of age-associated amyloid disorders, specifically SSA, CAA, and AGel 
amyloidosis.
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1. AMYLOID
1.1. The term “amyloid” – historical aspects
The term “amyloid” was coined in the year 1838 by the German botanist 
Matthias Schleiden to describe a normal amylaceous constituent in plants 
(Kyle, 2001). In the medical literature, the term was used in 1854 for the first 
time by Virchow (Virchow, 1854a) who noted that small round deposits in 
the nervous system showed the same color reaction with iodine and sulfuric 
acid, a change from brown to blue which was typical for starch. Based on 
this, he was convinced that these structures were identical to starch (Virchow, 
1854b) and named them “corpora amylacea” after the Latin term “amylum” 
(starch). In contrast to Virchow, representatives from the French and British 
Edinburgh schools thought that amyloid was more closely related to cellulose 
than starch. They preferred to use the terms “lardaceous” (based on the 
bacon-like appearance of the tissue) or “waxy” (based on the homogeneity 
of the material). These schools also used the term “sago” (a sweet substance 
in certain palm species) to describe a spleen, in which the follicles were 
converted into the waxy material.
Notable milestones in the history of amyloid after its first account by 
Virchow are listed in Table 1. A new insight into the biochemical character 
of amyloid was attained in 1859 when Friedrich and Kekule (Kyle, 2001) 
reported a high proportion of nitrogen in amyloid-infiltrated organs. This led 
to the idea that amyloid was composed of proteins instead of carbohydrates. 
Virchow never agreed with this theory, which is now known to be correct. 
In 1875, further progress took place in the diagnostics field when Cornil in 
Paris, Heschl in Vienna, and Jürgens in Berlin independently described the 
usefulness of methylviolet staining to detect amyloid, compared to Virchow’s 
iodine sulfuric acid test (Kyle, 2001). Methylviolet is a “metachromatic” 
stain, a term introduced in 1878 by Ackroyd and Ehrlich to describe the 
staining reaction of amyloid (Kyle 2001). Nevertheless, Virchow rejected the 
metachromatic stains of amyloid as long as 10 years after their discovery. 
However, the metachromatic stains were helpful in 1876 in detecting 
amyloid in heart tissue (Soyka J. Prag Med Wschr 1: 165, 1876; cited in 
Hodgkinson [Hodgkinson and Pomerance, 1977] and Buerger [Buerger 
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and Braunstein, 1960], Table 1). Eventually, metachromatic staining was 
replaced by Congo red. In 1907, Alzheimer described “senile” plaques and 
neurofibrillary tangles in a demented patient (Alzheimer et al., 1907, Table 
1). Later, in 1927, Divry reported amyloid material within senile plaques in 
Alzheimer’s disease (Divry P. Etude histo-chimique des plaques seniles. J de 
neurologie et de Psychiatrie 27: 643-657, 1927; cited in Kyle [Kyle, 2001]). 
In 1954, cerebrovascular amyloid was described by Pantelakis (Pantelakis 
S. A particular type of senile angiopathy of the central nervous system: 
congophilic angiopathy, topography and frequency [Article in French]. 
Monattsschr Psychiatr Neurol 128:219-256, 1954).
Table 1. Notable years in the history of amyloid and amyloid diseases, with special 
focus on SSA, CAA, and AGel amyloidosis.
Year Event
1854 Virchow introduces the term “amyloid” into the medical literature
1859 Friedrich and Kekule report on nitrogen in amyloid deposits
1876 Soyka describes cardiac amyloid
1884 Böttiger creates Congo red dye
1907 Alzheimer et al. describe senile plaques and neurofibrillary tangles
1922 Bennhold notes that Congo red binds to amyloid 
1927 Divry et al. describe Congo red in senile plaques
1954 Pantelakis introduces the term “congophilic angiopathy”
1959 Cohen and Calkins describe the fibrillar ultrastructure of amyloid in EM
1962 Puchtler introduces a new modification of Congo red
1968 Eanes and Glenner describe the secondary (X-ray diffraction) structure of amyloid 
1968 Pras introduces a method to extract proteins from fibrils
1979 Meretoja describes Finnish type (AGel) amyloidosis
1980 Sletten et al. detect prealbumin (TTR) as the main amyloid fibril protein in “senile 
cardiac amyloidosis” 
1984 Pitkänen et al. introduce the term SSA
1984 Glenner and Wong describe cerebrovascular Aβ protein
1990 Ghiso et al. and Maury et al. describe variant gelsolin as an amyloid protein in 
AGel amyloidosis
1995 Gustavsson et al. propose that TTR fibrils are composed of wildtype protein in SSA
SSA = senile systemic amyloidosis; CAA = cerebral amyloid angiopathy; 
AGel amyloidosis = hereditary gelsolin amyloidosis; EM = electron microscopy; 
TTR = transthyretin.
A substantial advance in amyloid research took place in the late fifties, 
when the fibrillar ultrastructure of amyloid was discovered using electron 
microscopy (EM) in 1959 (Cohen AS and Calcins E. Nature 183: 1202-3, 
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1959; cited in Vinters [Vinters, 1996]). Another advancement was made 
in 1966 when the pentagonal protein serum amyloid P component was 
described (SAP; Bladen HA, Nylen MU, Glenner GG. Ultrastruct Res 14: 
449-59, 1966; cited in Kyle [Kyle, 2001]). Two years later, a significant step 
forward in the chemical characterization of amyloid proteins took place 
when a method to extract proteins from fibrils using water was introduced 
(Pras et al., 1968), enabling the rapid identification of new amyloid proteins. 
In 1971, the biochemical basis of AL amyloidosis was unraveled (Glenner 
et al., 1971). During the subsequent years, AA amyloid was characterized 
as an amyloid protein in the previously called “secondary” (inflammation-
associated) amyloidosis (Benditt EP, Eriksen N. Lab Invest 26: 615-25,1972; 
cited in Kyle [Kyle, 2001]). In addition, serum amyloid A protein, an acute 
phase protein, was soon identified in blood (Levin M, Pras M, Franklin 
EC. J Exp Med 138: 373-80, 1973; cited in Kyle [Kyle, 2001]; Husby and 
Natvig, 1974). In 1978, prealbumin (transthyretin, TTR) was found to 
be characteristic for amyloid material in familial Portuguese amyloid 
polyneuropathy (FAP; Costa et al., 1978); a clinical disease described already 
in 1951 (Corino de Andrade, M. Preliminary note on an unusual form of 
peripheral neuropathy. Rev Neurol (Paris) 85: 302-6, 1951; cited in Kyle 
[Kyle, 2001]). In 1979, Meretoja described Finnish amyloidosis, now known 
as AGel amyloidosis (Meretoja, 1979). In 1980, TTR was found to be the 
characteristic protein in “senile cardiac amyloidosis” (SCA; Sletten et al., 
1980). SCA was later renamed senile systemic amyloidosis (SSA), in order to 
emphasize the systemic nature of this wildtype TTR-associated amyloidosis 
(Cornwell et al., 1983; Gustavsson et al., 1995). In 1983, cystatin-C was found 
to represent the protein characteristic of amyloid in the Icelandic type of 
familial cerebral amyloid angiopathy, (HCHWA-I; Cohen et al., 1983) and 
in the same year, a point mutation in the gene coding for TTR, resulting in a 
substitution of methionine instead of valine at position 30, was reported for 
FAP (Tawara et al., 1983). In 1984, Glenner and Wong gave the first report 
on the AD-associated cerebrovascular Aβ (Glenner and Wong, 1984a) and 
the following year beta 2 -microglobulin was described to characterize the 
amyloid in the dialysis-related amyloid arthropathy (Gejyo et al., 1985). In 
1988, apolipoprotein A1 (APOA1) was characterized as the amyloid protein 
in the hereditary amyloid disease in Iowa, USA (Nichols et al., 1988). In 1990, 
variant gelsolin was described as the amyloid protein in the Finnish form of 
FAP, now preferentially referred to as hereditary AGel amyloidosis (Ghiso 
et al., 1990; Maury et al., 1990). Later, several proteins were characterized 
describing three different familial amyloid diseases showing a preference for 
renal manifestation: fibrinogen A-α chain (Benson et al., 1993), lysozyme 
(Pepys et al., 1993) and apolipoprotein AII (Benson et al., 2001).
Major progress has taken place in amyloid research during the last 150 
years. It is now clear that the cerebral corpora amylacea are not composed 
of proteins, but glycogen-like substances with sulfate and phosphate groups 
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as Virchow claimed. Furthermore, it is also clear that cerebral corpora 
amylacea do not represent amyloid. Interestingly, the term “amyloid” has still 
prevailed. The reason for this resides in history, based partly on Virchow’s 
standing as one of the leading pathologists of his time and partly on iodine 
staining, which was used for a long time as the diagnostic test for amyloid 
(Doyle, 1988). 
1.2. Structure
1.2.1. congophilia with apple-green birefringence
Congophilia with apple green birefringence (Divry P. Etude histo-chimique 
des plaques seniles. J de Neurologie et de Psychiatrie 27:643-57, 1927; cited 
in Sipe [Sipe, 2000]) was the first criterion for amyloid (Sipe, 2000). Congo 
red dye was invented by the German chemist Böttiger already in the year 
1884 (Böttiger P. Deutsches Reich’s Patent 28753, August 20, 1884; cited 
in Frid [Frid et al., 2007]). Congo red is an aniline dye originally used 
for staining textiles, but is also capable of staining all types of amyloid. 
Böttiger created the first “direct” dye, which did not require additional 
substances for fixation to the textile fibers. The name “Congo” was given to 
the new dye by the owner of the patent, the AGFA Corporation, inspired 
by a diplomatic conference held in Berlin in 1884-1885 in order to mediate 
a trade dispute between several European colonial powers in the Congo 
River Basin in Central Africa (Kyle, 2001; Steensma, 2001). The name was 
thought to be effective for marketing purposes since “Congo” referred to 
an exotic place, and moreover, in those days it was on the “tip of the lips” 
(Kyle, 2001; Steensma, 2001). In addition to staining textiles, Congo red was 
used to stain tissues already in 1886 (Steensma, 2001), but it was not until 
1922 that Bennhold noted its capacity to bind to amyloid (Bennhold H. 
Eine spezifische Amyloidfärbung mit Kongorot. Münchener Medizinische 
Wochenschrift (November):1537-1538, 1922; cited in Kyle [Kyle, 2001]). 
In the year 1962, Puchtler described the renewed method (Puchtler et al., 
1962) which is still widely used. 
The chemical name of Congo red (also known as ”direct red”, “direct red 
28”, or “cotton red”) is 3,3΄-[(1,1´-biphenyl)-4,4´-diylbis(azo)] bis-(4-amino-
1-naphtalene acid) disodium salt (C32H22N6O6S2·2Na). It is a symmetrical 
molecule with a hydrophobic center and is composed of two phenyl rings. 
The rings are linked via diazo bonds to two charged terminal naphtalene 
moieties. The terminal parts of Congo red contain sulphonic acid and 
amine groups, and it has a molecular weight of 696.7 g/mol and diameter 
of approximately 21Å (Romhanyi, 1971). Congo red exists in chinone form 
in acidic solution, and in sulphonazo form in basic solution, changing the 
color from blue (below pH 3) to red (above pH 5) and can thus be used 
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as a pH indicator as well. The binding of Congo red to amyloid induces a 
characteristic shift in the maximal optical absorbance of the molecule from 
490 nm to 540 nm. The mechanisms of interaction between Congo red and 
amyloid fibrils has been intensively studied (Klunk et al., 1989; Turnell and 
Finch, 1992) but the process is not completely understood (Frid et al., 2007). 
Generally, it is believed that Congo red binding depends on the secondary, 
β-pleated configuration of the fibril, and is possibly mediated by hydrophobic 
interactions of the benzidine centers as well as the electrostatically charged 
terminal groups (Frid et al., 2007).
The Puchtler modification (Puchtler et al., 1962) of Congo red staining is 
widely used in pathology as the first step in detecting amyloid in histological 
specimens, although individual laboratories may apply their own variant 
of the method. Congo red staining is also applicable to frozen sections 
and for staining devices. In diagnostics, the formalin-fixed histological 
samples are generally embedded in paraffin, sectioned 5-8 μm thick (brain 
samples), stained with Congo red, and viewed in a light microscope under 
polarized light in which amyloid can be seen as red to green birefringent 
homogeneous material. Interestingly, the light microscope finding has been 
recently observed to vary in different types of transthyretin (TTR)-related 
amyloidosis. Therefore, distribution into two different histological patterns 
of amyloid deposition (designed as A and B) has been proposed (Bergstrom 
et al., 2005). In pattern A, seen in SSA and in some TTR-associated FAP 
cases, amyloid material is noted to have a homogenous, patchy distribution 
displaying only weak congophilia. In pattern B, detected in part in FAP 
patients, amyloid appears as thin streaks and is strongly congophilic. After 
this proposal, the biochemical structure of amyloid fibrils was supposed to 
be transmitted to the microscopic finding.
1.2.2. Fluorescence microscopy
Amyloid can also be visualized using a fluorescence microscope. A 
fluorescence microscope is a light microscope used to study the properties 
of organic and inorganic substances using the phenomena of fluorescence 
and phosphorescence. The component of interest in the specimen is labeled 
with a fluorescent molecule called the fluorophore. However, fluorophores, 
lose their ability to fluoresce as they are illuminated. In fluorescence 
microscopy, amyloid can be detected using thioflavin stains which emit 
green fluorescence when they are bound to amyloid. Thioflavin-T (Basic 
Yellow 1 or CI 49005) is a benzothiazole salt, obtained by methylating 
dehydrothiotoluidine with methanol in the presence of hydrochloric acid. 
When the dye binds to β sheets, it undergoes a characteristic 120 nm red 
shift of its excitation spectrum that may selectively be excitated at 450 nm, 
resulting in a fluorescence signal at 482 nm. Thioflavin-S is a mixture of 
compounds resulting from the methylation of dehydrothiotoluidine with 
sulphonic acid. Both thioflavin-T and -S stains can be used to visualize 
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amyloid. Although the fluorescence method is also specific for amyloid 
(Revesz et al., 2003), the loss of fluorescence is disadvantageous since the 
reaction cannot be re-examined later.
1.2.3. Fibrillar morphology
The fibrillar morphology of amyloid, based on the analysis of contrasted 
tissue sections by EM (Cohen and Calkins, 1959), has been adopted as the 
second criterion defining amyloid (Sipe and Cohen, 2000). Of the several 
types of EM, scanning transmission and single particle molecular averaging 
EM have been considered to be very powerful in modern amyloid research 
(Lashuel and Wall, 2005). The technique used to prepare the sample material 
for EM varies depending on the specimen and the analysis required. In 
order to detect amyloid, the samples are usually dehydrated, embedded with 
a resin such as epoxy, sectioned into thin slices, and stained using heavy 
metals such as lead, uranium, or tungsten. The idea of staining is to scatter 
imaging electrons and to create contrast between different structures, since 
many materials, particularly biological materials, are nearly transparent 
to electrons. In biology, specimens are usually stained “en bloc” before 
embedding, and then stained directly after sectioning by brief exposure 
to aqueous or alcoholic solutions of the heavy metal stains. In the original 
work of Cohen and Calkins, the sections were stained with uranyl acetate 
and lead citrate. 
The ultrastructure of amyloid deposits of diverse origins in humans and 
animals (Cohen A.S. et al, Electron microscopy of amyloid in Harris J.R. 
(ed.) Electron Microscopy of Proteins, Vol 3, pp. 165-205) consist of straight, 
rigid fibrils ranging in width from 6-13 nm (10 nm=100Å), on average 7.5 to 
10 nm, and a length ranging from 100-1600 nm. Two or more filamentous 
subunit structures, 2.5 to 3.5 nm in diameter, occasionally crossing each 
other, longitudinally constitutes this 7.5-10 nm -wide amyloid fibril. 
1.2.4. secondary structure: the pleated beta (β) sheet
The secondary structure, typical to all amyloids, was revealed by X-ray 
diffraction analysis of isolated amyloid protein fibrils (Eanes and Glenner, 
1968; Bonar et al., 1969; Sunde and Blake, 1997). 
The initial isolation method of amyloid fibrils was based on a gentle 
physical separation and homogenization in saline, followed by low-speed 
centrifugation, yielding a layer of fibrils not present in sedimentation pellets 
of normal tissues (Cohen and Calkins, 1964) and demonstrating a green 
birefringence in polarized light after staining with Congo red. Amyloid 
fibrils isolated from tissues and organs by a physical separation model using 
sucrose gradient centrifugation (Shirahama and Cohen, 1967) was also 
equal in morphology to those tissues. Pras introduced the water extraction 
method (Pras et al., 1968) that has been widely used for extracting almost all 
biochemical types of amyloid except Aβ and prion protein amyloid (Selkoe 
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and Abraham, 1986; Prusiner and DeArmond, 1990). With the low ionic 
strength Pras method, amyloid fibrils are separated from all proteins soluble 
in physiological saline by extraction of homogenates of amyloid-laden tissues 
with physiological saline, followed by differential centrifugation. Then, 
amyloid fibrils can be separated from other saline-insoluble tissue proteins 
by suspension in water.
In nature, most proteins have both alpha helix and beta (β) sheet 
secondary structure. In the amyloid form, the proteins are mostly in the 
β-pleated sheet conformation though not exclusively. Factors influencing 
changes in the spatial form of proteins include increased protein content, low 
pH, metal ions and chaperones, proteins that are associated with amyloid 
deposits but are not part of the insoluble fibrils themselves (see later; Ghiso 
and Frangione, 2002). The secondary structure of amyloid consists of the 
polypeptide backbone, mostly in the β-pleated sheet conformation, oriented 
perpendicular to the fibril axis.
1.2.5. Amyloid fibril proteins and their nomenclature
The modern nomenclature of different types of amyloid (Table 2) is based on 
the amyloid fibril protein. An informal amyloid nomenclature committee was 
established in 1974 in Helsinki, Finland, in connection with the first Internal 
Symposium on Amyloidosis. Thereafter, the committee has met several times 
in order to create the official nomenclature lists for each type of amyloid 
(Westermark et al., 2005). For the amyloid fibril protein to be included in 
the official nomenclature list, it must be unambiguously characterized and 
described in a peer-reviewed paper. According to the present nomenclature, 
amyloid is formed on extracellular deposits of proteins. Apart from these 
extracellular fibril proteins, several intracellular protein inclusions have 
been described, and except for neurofibrillary tangles, these proteins are 
not included in the amyloid list. The current lists for human (Table 2) and 
animal amyloid fibril proteins have been presented by Westermark et al. 
(Westermark et al., 2005), and include a separate list of inclusions with 
aggregated proteins of known biochemical composition, with or without 
amyloid properties (Westermark et al., 2005).
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Table 2. Human amyloid fibril proteins and their precursors.
Amyloid  
protein
Precursor protein Type Syndrome/Involved tissue
AA (Apo)serum AA S Reactive (previously: “secondary”)
AANF Atrial natriuretic factor L Cardiac atria
AApoAI Apolipoprotein AI
S
L
Familial
Aorta, meniscus
AApoAII Apolipoprotein AII S Familial
AApoAIV Apolipoprotein AIV S Sporadic, aging
ABri ABriPP S Familial dementia, British
ACal (Pro)calcitonin L C-cell thyroid tumors
ACys Cystatin C S Familial
ADan ADanPP L Familial dementia, Danish
AFib Fibrinogen α-chain S Familial
AGel Gelsolin S Familial (previously: “Finnish”)
AH Immunoglobulin heavy chain S; L
Myeloma-associated 
(previously: “primary”)
AIAPP
Islet amyloid polypeptide
(previously: “amylin”)
L
Insulinomas, aging
Islets of Langerhans
AIns Insulin L Iatrogenic
AKer Kerato-epithelin L
Familial
Cornea
AL Immunoglobulin light chain S; L
Myeloma-associated
(previously: “primary”)
ALac Lactoferrin L Cornea
ALys Lyspzyme S Familial
AMed Lactadherin L Aortic and arterial media, aging
AOAAP Odontogenic ameloblast-associated protein L Odonogenic tumors
APro Prolactin L
Prolactinomas, aging 
Pituitary gland
APrP Prion protein L Spongiform encephalopathies
ASemI Semenogelin I L Vesicula seminalis
ATau Tau* L
Aging, AD, FTL**
Intracellular
ATTR Transthyretin
S
L?
Familial, SSA
Tenosynovium
Aβ Aβ protein precursor (AβPP) L Aging, AD, CAA
Aβ2M β2-microglobulin S; L?
Hemodialysis-associated
Joints
S = systemic; L = localized; FTL = frontotemporal dementia; SSA = senile systemic amyloidosis;  
CAA = cerebral amyloid angiopathy.
*intracellular.
**and other cerebral conditions.
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In addition to fibril proteins, amyloid deposits contain other proteins (Table 
3), which are not part of the insoluble fibrils themselves, called “pathological 
chaperones” (Ghiso and Frangione, 2002). These proteins include amyloid P 
component, apolipoprotein E (APOE), apolipoprotein J, glycosaminoglycan 
perlecan, vitronectin, α1-antichymotrypsin, and complement proteins (Sipe, 
1992; Revesz et al., 2003; Buxbaum, 2006).
Table 3. Proteins associated with amyloid fibrils (“pathological chaperones”).
Protein Reference
Amyloid P-component Pepys et al., 1994
Apolipoprotein E Gallo et al., 1994
Apolipoprotein J Yerbury et al., 2007
Complement Matsuoka et al., 2001
Perlecan Ancsin and Kisilevsky, 1999
Vitronectin Eikelenboom et al., 1994
α1-antichymotrypsin Ma et al., 1994
1.3. Formation of amyloid
The present hypothesis on the process of amyloid formation suggests that the 
amyloidogenic precursor proteins undergo misfolding, which allows them 
to populate an immediate precursor pool, from which they rapidly aggregate 
(Buxbaum, 2004). Depending on the particular protein, several mechanisms 
are operative and may involve: nonphysiological proteolysis, defective 
physiological proteolysis, and mutations with changes in thermodynamic 
or kinetic properties, resulting in oligomeric aggregation. This is followed 
by the assembly of higher order structures that become insoluble under 
physiological conditions.
For a long time, fibrils found in tissues were thought to be biochemically 
and structurally identical to the isolated amyloid protein fibrils used in in 
vitro studies (Sipe and Cohen, 2000). However, dissimilarities have been 
found between amyloid fibrils in tissue deposits and isolated preparations 
using high resolution EM (Inoue et al., 1998). In addition, in vitro studies 
suggest that the formation of amyloid fibrils is the result of a combination 
of factors, not only including the primary structure of the polypeptide, 
but also the thermodynamic parameters of the environment (Kelly, 1998). 
Thus, results from in vitro studies should only cautiously be applied to in 
situ tissues.
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1.4. Genetics and amyloid
In the field of amyloid research, genetic analyses have been focused on 
two different areas. First, genetic modifications in precursor proteins can 
influence amyloid fibril formation since point mutations in the coding 
region of a gene can cause amino acid substitutions, influencing amyloid 
fibril formation (Revesz et al., 2003). These mutations can influence or alter 
the rate of conversion of a native protein to the fibrillar form. Examples of 
this include the amyloidogenic variant of cystatin-C deposited in hereditary 
cerebral hemorrhage with amyloidosis, Icelandic type (HCHWA-I), or 
the enhanced amyloidogenic properties of the mutant E22Q Aβ peptide 
which is associated with hereditary cerebral hemorrhage with amyloidosis, 
Dutch type (HCHWA-D). Other possible genetic modifications of precursor 
proteins resulting in amyloid formation include truncation (e.g. Gerstmann-
Sträussler-Scheinkler with YI45STOP of the prion protein) and elongation 
(e.g. ABri and ADan precursor proteins in the BR12 gene -related dementias) 
(Revesz et al., 2003). The second role of genetics in amyloid research is in 
the investigation of possible associations between clinical amyloid diseases 
and genetic alterations. Well-known examples of this include the multiple 
mutations in the gene for TTR in FAP syndromes, or the established 
association between the APOE ε4 allele and AD.
2. OLD AGE-ASSOCIATED AMYLOID DISEASES
2.1. General aspects
The age-related amyloid diseases (Table 4) have come of age (Cornwell et al., 
1995). Among them, AD has received the most attention, although during the 
last two decades several other amyloid diseases manifesting at old age have 
been identified. In addition, causative fibril proteins have been recognized 
but common amino acid sequences in the amyloid fibril proteins causing 
the age-related amyloid diseases have not been identified (Cornwell et al., 
1995). The old age-associated amyloid diseases include SSA and amyloidosis 
associated with AD, including CAA, senile aortic (AMed) amyloidosis, 
isolated atrial amyloidosis, amyloidosis of the seminal vesicles, amyloidosis 
of the islets of Langerhans, and amyloidosis of the pituitary gland (Cornwell 
et al., 1995). Of these, only SSA is a systemic disorder. The others occur in 
a single localization only, and the fibril protein precursors are synthesized 
locally in the tissue involved. In SSA, the precursor protein is synthesized 
mainly in the liver. There are also some age-associated intracellular amyloid 
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forms, like the neurofibrillary tangles in neurons in AD, the choroid plexus 
amyloid (Eriksson and Westermark, 1986), and adrenal cortical amyloid 
(Eriksson and Westermark, 1990). In several hereditary forms of amyloid 
diseases, symptoms may manifest only in middle age, or even old age, 
although the genetic defect is already present at birth. In this sense, the 
hereditary amyloid diseases are also associated with aging. 
Table 4. The old age-associated amyloid diseases.
Disease* Amyloid protein Reference
Alzheimer’s disease Aβ, 
Tau**
Masters et al., 1985
Grundke-Iqbal et al., 1986a
AMed (senile aortic) amyloidosis AMed Haggqvist et al., 1999
Amyloidosis of the adrenal cortex Inclusion bodies** Eriksson and Westermark, 1990
Amyloidosis of the choroid plexus Tau** Eriksson L and Westermark, 1986
Amyloidosis of the islets of Langerhans AIAPP Westermark et al., 1990a
Amyloidosis of the pituitary gland APro*** Westermark et al., 1997
Amyloidosis of the seminal vesicles ASemI Linke et al., 2005
CAA Aβ Glenner and Wong, 1984a
Isolated atrial amyloidosis AANF Rocken et al., 2005
SSA ATTR Sletten et al., 1980
CAA = cerebral amyloid angiopathy; SSA = senile systemic amyloidosis.
*Note: hereditary amyloid diseases are not included in this list.
**Intracellular deposition.
***Occasionally other pituitary hormone.
Apart from age and heredity, amyloid formation may be associated with 
several other conditions including malignant neoplasms, chronic dialysis, 
or chronic inflammation such as rheumatoid arthritis. In the following 
chapters, four forms of age-associated amyloid diseases are presented: SSA, 
CAA, hereditary AGel-, and AMed amyloidosis.
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Figure 1.
Amyloid material deposited in the myocardium (arrow) in SSA shows red (A) to green (B) 
birefringence after Congo red staining (A,B) viewed in polarized light (B), and reactivity in 
anti-TTR immunohistochemistry (C). Fibrous scar tissue (asterisk), easy to recognize in the 
connective tissue staining (Herovichi; D) compared to HE staining (E), reacts in the anti-alpha2-
macroglobulin immunohistochemistry (F). Original magnification: 400x. Scale bar: 100μm.
2.2. Senile systemic amyloidosis (SSA)
2.2.1. definition, clinical characteristics, and  
    histological findings
In SSA, wildtype TTR-derived amyloid (Figure 1) is deposited in parenchymal 
organs, mainly in the heart. Since amyloid in heart tissue was described 130 
years ago (Soyka J. Prag Med Wschr 1: 165, 1876;. cited in Hodgkinson 
[Hodgkinson and Pomerance, 1977]), a substantial time elapsed until SSA 
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was precisely defined in 1984 (Pitkanen et al., 1984). The first step was 
the identification of prealbumin (TTR) in the amyloid deposits of SSA 
(referred to as “senile cardiac amyloidosis or “SCA” at that time; Sletten et 
al., 1980). As the exact composition of amyloid fibrils was not known at the 
time, a form of hereditary TTR-related amyloidosis called TTR Ile122Val 
(see Review of the literature, Chapter 2.2.4.2.), was first reported as “SSA” 
(Gorevic et al., 1989b; Jacobson et al., 1990). In 1995, the designation SSA 
was proposed “only for TTR amyloidosis occurring in advanced age and in 
the absence of TTR variant” (Gustavsson et al., 1995). The designation of 
SSA is included in the current nomenclature of amyloid diseases (Table 2; 
Westermark et al., 2005).
Previous results from hospital-derived series show that SSA is detected 
in one-fourth of individuals over 80 (Cornwell et al., 1983; Westermark 
et al., 2003), but population-based studies are lacking. SSA is clinically a 
benign disorder (Cornwell et al., 1995), although it can cause cardiac failure, 
conduction disorders, and arrhythmias (mainly atrial fibrillation observed 
in a few patients) (Johansson and Westermark, 1991; Pitkanen et al., 1984). 
Previously, a weak tendency for myocardial infarctions (MIs) in SSA patients 
has been proposed but no association with coronary atherosclerosis has been 
found (Cornwell et al., 1983). In an article by Johansson et al. (Johansson 
and Westermark, 1991), none of the twelve patients with massive amyloid 
infiltration due to SSA showed atrioventricular dissociation, and in none 
of the patients were conduction disturbances considered to represent the 
cause of death.
The diagnostic tools for cardiac amyloidosis include electrocardiography 
(ECG), echocardiography, angiocardiography, and technetium scanning 
(Stone, 1990; O’Hara and Falk, 2003). Recently, a promising noninvasive 
etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-Diphosphono-1,2-
Propanodicarboxylic Acid Scintigraphy has been proposed (Perugini et al., 
2005). However, for the purpose of identifying the insoluble amyloid fibrils 
in the tissue and defining the type of amyloid in order to choose a proper 
treatment, a histological sample is essential −(e.g. myocardial biopsy in the 
case of cardiac amyloidosis)− (Kyle et al., 1996; Hughes and McKenna, 2005). 
Even today, although it is possible to clinically diagnosis cardiac amyloidosis 
using the above mentioned diagnostic tools, SSA is mainly detected only 
by chance at the time of autopsy (Pitkanen et al., 1984; Kyle et al., 1996). 
Clinically, the AL (light chain, myeloma-associated) amyloidosis is the 
major differential diagnosis of SSA. The distinction is essential as SSA and 
AL amyloidosis are clearly distinct regarding prognosis and therapy (Kyle 
et al., 1996).Patients with AL amyloidosis benefit solely from chemotherapy, 
although they usually do not survive beyond six months (Dubrey et al., 
1998; Dubrey et al., 2001). In contrast, the clinical consequences of SSA are 
generally minor, however recommendations for treating heart insufficiently 
are mostly not useful, and the use of digitalis preparations or excitative 
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β-adrenergic blockers may even be harmful (Kyle et al., 1996). Interestingly, 
a successful heart transplantation in a 68-year-old patient with SSA was 
recently reported (Fuchs et al., 2005).
In SSA, amyloid deposits have been detected in all tissues except the brain 
(Pitkanen et al., 1984). However, there are no reports on clinical consequences 
from SSA deposits in extracardial tissues. In most organs or tissues, amyloid 
deposits are mainly present in the blood vessel walls. However, in the heart 
they are also observed as diffuse or multifocal infiltrations between the 
heart muscle cells in the ventricles and atria (Cornwell et al., 1995), mostly 
sparing the specialized conduction tissue (Johansson and Westermark, 1991). 
Amyloid deposition in the myocardium leads to restrictive cardiomyopathy 
(RC). RC can be due to several conditions, and it can be divided into the 
primary and secondary types (Hughes and McKenna, 2005). The primary 
type of RC includes endomyocardial fibrosis, Löeffler’s endocarditis, 
and idiopathic RC. The secondary type consists of non-infiltrative and 
infiltrative conditions. Non-infiltrative conditions include carcinoid heart 
disease and anthracyclin toxicity, while infiltrative conditions include 
amyloidosis, sarcoidosis, and the storage diseases. Determining the reason 
for RC is essential because the principles of medical treatment for amyloid 
cardiomyopathy clearly differ from other diseases causing RC (Olson et al., 
1987; Hughes and McKenna, 2005).
2.2.2. Genetic and other risk factors for ssA
Apart from reports in non-population based series of age being a risk factor 
for SSA (Cornwell et al.; 1983, Westermark et al., 2003), no published data 
have been available on other risk factors.
2.2.3. synthesis, structure, and function of transthyretin (ttr)
TTR, synthesized mainly in the liver (Skrede et al., 1975), is a 147 amino 
acid proprotein chain (MW 55kD), encoded by a single copy gene on 
chromosome 18. Some TTR synthesis also takes place in the choroid plexus 
in the brain (Li et al., 1997; Monteiro et al., 1998; Zheng et al., 1999), in 
the uvea (Kawaji et al., 2005), and in the islets of Langerhans (Jacobsson, 
1989). After the signal sequence of 20 amino acids is cleaved off, the 127 
amino acid monomeric TTR forms dimers and tetramers. The tetrameric 
form of TTR present in serum is capable of binding two molecules of 
thyroxine and has independent binding sites for retinal binding protein. 
Each monomer contains two segments of β-pleated sheets. Whereas the TTR 
variant associated with FAP invariably contains a mutation, the structure 
of the TTR protein in SSA is normal (Cornwell et al., 1988; Westermark et 
al., 1990b). In addition, no mutation in the gene coding for TTR has been 
detected (Christmanson et al., 1991; Gustavsson et al., 1995).
In the study by Gustavsson et al., the amyloid fibrils of SSA contained 
intact TTR together with a family of TTR fragments, the longest of which 
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consisted of the –COOH terminal amino acids 46-127 (Gustavsson et al., 
1995). The proteolytic cleavage was not random, and the cleavage of the 
TTR molecule at the same positions has been described in TTR-related 
FAP as well (Gorevic et al., 1989c; Pras et al., 1983; Hermansen et al., 
1995). Fragments of consistent length have been found in a number of 
SSA hearts, and in both FAP and SSA, these fragments may predominate 
over the presence of full-length TTR molecules (Cornwell et al., 1995). The 
mechanism of wildtype TTR-based amyloid fibril formation in humans is not 
understood completely, but the fragments are thought to have an important 
role (Cornwell et al., 1995). In vitro biophysical experiments indicate that the 
TTR fibrillogenesis process presumably requires the dissociation of the native 
tetramer into its constituent monomers (Kelly et al., 1997; Reixach et al., 
2004). A conformational change within the monomer (“misfolding”) enables 
the formation of soluble aggregates which become insoluble protofilaments. 
This may be followed by the self-assembly of four protofilaments to form 
amyloid fibrils (Kelly, 1998; Quintas et al., 2001; Reixach et al., 2004).
2.2.4. ttr-variants
More than one hundred variants of the TTR protein, arising from point 
mutations in its gene, have been discovered. These mutations destabilize 
the TTR molecule by lowering the energy requirement for tetrameric 
dissociation (Koo et al., 1999), and thus predisposing the molecule to fibril 
formation. Most of the variants are rare. The age of onset of the symptoms, 
the pattern of organ involvement, and the course of disease caused by 
the variants differ according to the type of mutation. The organs that are 
most often involved are the peripheral nerves (hence the name familial 
amyloidotic polyneuropathy; FAP) and the heart. Apart from the variants 
leading to clinical disease, there are also non-amyloidogenic variants. Only 
six TTR variants have been reported from Scandinavia (Suhr et al., 2003; 
Holmgren et al., 2005), and none in Finland. The nomenclature of the TTR 
variants in the current database (http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?CMD=search&DB=snp) also takes the 20 amino acids signal sequence 
into account. 
TTR Val30Met (replacement of methionine for valine at position 30) was 
the first variant described. It appears mainly in Portugal, Japan, Sweden, 
and the United States. The patients have systemic amyloidosis involving the 
autonomic nervous system and heart. Liver (Holmgren et al., 1991) and heart 
transplantation (Suhr et al., 2003) may stop the progress of the disease. The 
Val122Ile variant carried by 3.9% of African Americans and over 5% of the 
population in West Africa represents the most common amyloid-associated 
symptomatic TTR variant worldwide (Jacobson et al., 1990; Jacobson et 
al., 1997), with patients developing late-onset amyloid cardiomyopathy. 
Interestingly, this variant was originally described as “SSA”(Gorevic et al., 
1989a). The variants Leu58His (Nichols et al., 1989) and Thr60Ala (Wallace 
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et al., 1986) cause carpal tunnel syndrome, with the latter also causing late-
onset systemic amyloidosis with cardiac involvement and polyneuropathy 
(PNP). These variants are mainly found in the United States and Germany. 
The Leu55Pro variant of TTR is the most amyloidogenic variant (Yang et al., 
2003) causing an early-onset aggressive diffuse amyloidosis with cardiac and 
neurologic involvement (Jacobson et al., 1992), and it has been described in 
the United States (original report) as well as Taiwan (Yamamoto et al., 1994). 
TTR Gly6Ser (designated as Gly26Ser in the present database: http://www.
ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&DB=snp) is the most 
common TTR variant, with an allele frequency of 0.06-0.09 in Caucasians. 
The variant is not amyloidogenic but carriers have shown an increased 
affinity for thyroxine binding (Akbari et al., 1990), leading to euthyroid 
hyperthyroxinaemia.
2.3. Cerebral amyloid angiopathy (CAA)
2.3.1. definition, clinical characteristics, and  
    neuropathological findings
CAA is characterized by amyloid deposition in the cortical (Figure 2A-C,F)
and leptomeningeal (Figure 2E, F) small- (Figure 2A-C,E) and medium-
sized (Figure 2F) blood vessels, mainly in the arteries although veins and 
capillaries can also be affected (Vinters, 1987; Revesz et al., 2003). This 
phenomenon was originally described by Pantelakis (Pantelakis, p. 18) and 
thus became known as “congophilic angiopathy of Pantelakis”. The most 
common form of CAA is the sporadic one, in which the major amyloid 
component consists of Aβ (Glenner and Wong, 1984a,b). Sporadic CAA 
is common in elderly individuals; its incidence in a general population 
aged ≥90 years was reported to range from 42.8% in men and 45.5% in 
women (Masuda et al., 1988) to 74% in both genders together (Masuda et 
al., 1988). The frequency of CAA escalates with increasing age (Masuda et 
al., 1988, Yamada et al., 1988 Xu et al., 2003). The role of CAA in normal 
aging is not clear, and only a few reports are available on animal models for 
sporadic CAA. Squirrel monkey (Saimiri spp.) is noted to develop significant 
CAA during natural aging, and this species is suggested to be a biologically 
advantageous model for studying the basic biology of idiopathic, age- related 
CAA (Elfenbein et al., 2007).
The distribution of CAA in the brain is patchy. This leads to difficulties 
in defining the extent of the occurrence and severity of the disease, as both 
depend on the number of brain areas included in the study. Due to this, 
several methods have been described in the literature to assess the extent 
and/or severity of CAA (Table 5). 
In previous studies, parenchymal CAA was most frequently encountered 
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Table 5. Semi-quantitative methods used to estimate the severity of CAA in human post mortem  
brain sections.
Method/ 
Reference
Scale Cerebral regions Staining 
method
Individual score Notes
Vonsattel 
et al. 1991
0-3 F, T, P, O Congo red -based on the most 
severe affected area only 
-the extent of histological 
CAA changes has no effect 
on the severity of the disease
-occipital lobe is not 
included
Olichney 
et al.1995
0-4 F, T, P, H Thioflavin-S -calculated by averaging 
the four regional scores 
-the staining reaction may 
vanish with time
Ellis et al. 
1996
0-3 F, T, P, H, E Congo red*
Thioflavin-S*
Aβ IHC*
-calculated by averaging 
the five regional scores
-occipital lobe is not 
included
- in some cases the diagnosis 
of amyloid is not based on 
recommended criteria
Thal et al. 
2002
0-2 T (3 regions), O Aβ IHC -a simplified 
combination of the 
extent and local severity 
of histological changes
-determining an individual 
score may be impossible in 
some cases, e.g. mild CAA 
in several regions
-the diagnosis of amyloid is 
not based on recommended 
criteria
F = frontal lobe; T = temporal lobe; P = parietal lobe; O = occipital lobe; H = hippocampus;  
E = entorhinal cortex.
*Note: Alternative methods; only one was used for each individual case.
in the frontal cortex, followed by the parietal and temporal lobes (Vinters 
and Gilbert, 1983; Ellis et al., 1996a). In AD patients, CAA has most often 
been encountered in the occipital cortex (Tian et al., 2003). The severity of 
CAA is associated with histopathologically determined AD changes: the 
neuritic plaques (Chapter 2.3.3.) and neurofibrillar tangles (Ellis et al., 1996; 
Yamada et al., 1988; Yamada, 2002). Clinically, CAA may be a diagnostic 
problem (Cederqvist et al., 1998). Mild CAA is not associated with clinical 
manifestations (Yamada, 2000), but severe CAA may cause cerebrovascular 
disorders such as cerebral hemorrhages and infarctions (Mandybur, 1986), 
leukoencephalopathy (Yamada, 2000), or dementia (Yoshimura et al., 1992; 
Greenberg et al., 1993; Olichney et al., 2000; Yamada et al., 1997a). 
CAA-related hemorrhage commonly occurs in superficial lobar regions 
of the cerebrum (Yamada, 2000). This differs from typical hypertensive 
hemorrhages which typically are not cortical, but in contrast occur within 
deep locations of the brain, often near the basal ganglia. In addition, CAA-
associated hemorrhages may occur in a normotensive patient, in contrast to 
the high blood pressure in patients with a hypertensive hemorrhage (Itoh et 
al., 1993). Further, CAA-related hemorrhage can be induced by anticoagulant 
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or antiplatelet therapy, and followed by a secondary subarachnoid hemorrhage 
(Itoh et al., 1993; Yamada et al., 1993). In addition to deposition of amyloid 
in the vascular walls (Figure 2) and subsequent obliteration of their lumens, 
histological features in severe CAA include the fibrinoid degeneration or 
necrosis of the vessel wall (Figure 2C; Okazaki et al., 1979, Rosenblum, 
1977), the “double barrel lumen” (Figure 2E); Okazaki et al, 1979; Gilbert 
and Vinters, 1983), and microaneurysm formation (Okazaki et al., 1979; 
Figure 2.
A cerebral cortical blood vessel (arrow) is positive in the Congo red staining (A,B) in polarized 
light (B) and is surrounded by as small cortical infarction (asterisk; A-D) and associated with 
infiltration of leukocytes (arrow head; A-D), which react in the anti–common leukocyte 
antigen (CD45, D) immunohistochemistry. Other typical features of severe CAA include hyaline 
degeneration (triangle; C), double contour of the vessel wall or “double barrel” (curled arrow; 
E), and minor blood extravasation identified by finding iron in the cytoplasm of macrophages 
(bent arrow; F). C,E: HE staining. Original magnification: 400x (A-E); 1000x (F). Scale bar: 100μm 
(A-E); 25μm (F).
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Vinters and Roos, 1996).
2.3.2. Genetic and other risk factors for cAA
The Apo E locus is the major susceptibility gene for late-onset AD, as 
studied in a high-density whole-genome association study (Polvikoski et 
al., 1995a; Coon et al., 2007). The APOE ε4 allele is also strongly associated 
with increased vascular Aβ deposits (CAA) in AD (Schmechel et al., 1993; 
Premkumar et al., 1996). In contrast, the APOE ε2 allele is highly frequent 
in patients with CAA-related hemorrhage (McCarron and Nicoll, 1998). 
CAA has been demonstrated in 80-90% of AD patients (Esiri and Wilcock, 
1986; Ellis et al., 1996; Yamada, 2000). In addition to being associated with 
AD (Ellis et al., 1996). CAA has also been associated with clinical dementia 
(Neuropathology Group. Medical Research Council Cognitive Function and 
Aging Study, 2001; Pfeifer et al., 2002). 
The severity of CAA is associated with the presenilin (PS)-1 intronic 
polymorphism (Yamada et al., 1997b) and with the GT repeat polymorphism 
in the gene for neprilysin (Yamada et al., 2003). In AD patients, the severity 
of CAA has been associated with the α1-antichymotrypsin A allele (Yamada 
et al., 1998a), whereas the T/C polymorphism at codon 10 (exon 1) of the 
TGFβ gene has recently been noted to be associated with the severity of CAA 
especially in non-AD patients and non -APOE ε4 carriers (Hamaguchi et al., 
2005). Some polymorphisms that have been shown to not be associated with 
CAA in humans include the: butyrylcholinesterase-K variant (Yamada et 
al., 1998b), exon 18 polymorphism of the α2M gene (Yamada et al., 1999b), 
interleukin-1A allele 2 (McCarron et al., 2003), cathepsin D exon 2 (C to 
T) polymorphism (Davidson et al., 2006), and in another study, the α1-
antichymotrypsin polymorphism (Sodeyama et al., 1999). 
The increased plasma homocystein levels are not associated with CAA 
(Irizarry et al., 2005). The development of CAA does not correlate with the 
presence of common cerebrovascular risk factors such as hypertension, 
diabetes mellitus, and hyperlipidemia (Yamada, 2000). The role of 
arteriosclerosis in CAA is somewhat unclear. A Japanese study did not 
detect a correlation between CAA and severity of atherosclerosis in the 
cerebral arteries (Yamada et al., 1987), although in a North American study 
a positive correlation between CAA and cerebral arteriosclerosis was found 
(Ellis et al., 1996).
2.3.3. synthesis and structure of amyloid beta protein (Aβ)
In 1984, Glenner and Wong reported the isolation of a 4200-dalton 
polypeptide, β-protein or Aβ, from amyloidotic vessels of AD and Down 
syndrome patients (Glenner and Wong, 1984a,b). This polypeptide was not 
present in any of the age-matched normal cerebral vessels they examined. By 
immunizing mice against a synthetic peptide identical to the first 10 residues 
of the β-protein and then using the antiserum immunohistochemically to 
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stain amyloid in cerebral vessels, this protein was detected in neuritic plaques 
one year later (Masters et al., 1985). The term “neuritic plaque” refers to 
plaques with thickened silver-positive neuritis (Mirra and Heyman, 1991) 
in which Aβ is aggregated into fibrils and forms amyloid (Yamaguchi et al., 
1990; Dickson, 1997). In contrast, plaques referred to as “diffuse” are devoid 
of abnormal neuritis and fibrillar amyloid. By using immunohistochemical 
techniques, several other types of plaques have later been identified (Delaere 
et al., 1991). In CAA, amyloid is formed from aggregated Aβ, similar to the 
neuritic plaques.
Aβ is a proteolytic fragment of the membrane-spanning amyloid 
precursor protein APP (Kang et al., 1987). In vivo, soluble Aβ is thought to 
gradually transform into the fibrillar form (Selkoe, 1991). Aβ has several 
isoforms, which tend to appear in varying localizations within various brain 
regions (Vinters et al., 1996). Biochemical analyses have indicated chemical 
distinctions in parenchymal and vascular amyloid (Prelli et al., 1988). For 
example, the carboxy-terminus of cerebrovascular Aβ is three amino acid 
residues shorter than Aβ in senile plaques (39 vs. 42 residues). In addition, 
the Aβ species deposited in blood vessel walls show both C- and N-terminal 
heterogeneity which can be demonstrated with specific antibodies (Revesz 
et al., 2003). Both immunohistochemical and biochemical studies have 
demonstrated that Aβ species ending at position 40 are predominantly 
deposited in the vessel walls in both sporadic and familial AD as well as in 
HCHWA-D (Castano et al., 1996). On the other hand, in addition to being 
present, Aβ 42 is sometimes the sole deposited peptide species in CAA 
in both humans and transgenic animals (Van Dorpe et al., 2000). These 
observations, also supported by in vitro experiments (Lansbury, 1997), 
suggest that the first Aβ species that are deposited in the vessel wall end at 
position 42, while the more soluble Aβ 40 is subsequently entrapped (Van 
Dorpe et al., 2000). An alternative possibility is that Aβ 40 is produced in 
situ by degradation of Aβ 42 by carboxypeptidases (Revesz et al., 2003). The 
N-terminal heterogeneity of Aβ, with a potential for enhanced aggregation, is 
also documented in CAA (Tekirian et al., 1998). This may imply that tissue-
specific endopeptidases may determine the differential processing of APP 
in the brain parenchyma and microvessel wall (Vinters et al., 1996).
The origin of both vascular and plaque Aβ in the brain is under debate. 
Vascular Aβ has been suggested to originate from blood or CSF, or as a local 
product of the smooth muscle cells in the blood vessel walls (Wisniewski 
and Wegiel, 1994; Vinters et al., 1996). Senile plaques are found in close 
proximity to brain capillaries (Miyakawa and Uehara, 1979; Miyakawa et al., 
1982). This lead to the hypothesis that capillary degeneration with resulting 
amyloid fibril formation might be a primary alteration in the genesis of senile 
plaques, yet another study suggests that the role of capillary degeneration in 
the evolution of senile plaques is minor (Kawai et al., 1990). Several types of 
structural alterations associated with amyloid deposition have been noted 
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in dendrites such as loss of dendritic spines, shaft atrophy, bending, abrupt 
branch endings, varicosity formation, and sprouting, in both a transgenic 
mouse model of AD and in human postmortem brain (Grutzendler et al., 
2007). These alterations may be due to the potential cytotoxicity of Aβ. 
The production of Aβ is under debate. In the classical view, the precursor 
protein AβPP is cleaved at the plasma membrane by α-, β-, and δ- secretases 
to produce Aβ, and that the cleavage product Aβ is rapidly expelled from 
the cell thereafter. Fitting this idea, the Aβ deposits in AD have traditionally 
been considered extracellular in nature. In addition to the cell surface, 
AβPP has been detected inside the cell in the endoplasmic reticulum and 
Golgi apparatus, and in recent studies using fluorescence resonance energy 
transfer and confocal microscopy, in human neuroglioma cells in close 
association to the centrosome (Nizzari et al., 2007). However, growing 
evidence indicates that Aβ peptide itself may accumulate intraneuronally. 
After the first observation in human neurons (Grundke-Iqbal et al., 1989), 
several reports on intracellular Aβ in human diseases and animal models 
have been presented (Chen et al., 2006; LaFerla et al., 2007), suggesting that 
Aβ can also be generated intracellularly (Wertkin et al., 1993; Tienari et al., 
1996; Hartmann et al., 1997).
Apart from neural tissue, Aβ is also detectable in the plasma and CSF 
in concentrations that hold the pool of brain Aβ in equilibrium with them. 
The influx of soluble Aβ across the blood brain barrier (BBB) depends on 
its interaction with the receptor for advanced glycocylated end products 
(RAGE) and low-density lipoprotein receptor (LRP) in the endothelium 
(Deane et al., 2004; Zlokovic, 2005). The clearance of Aβ from the brain and 
its implications in AD and CAA are discussed in detail in the Discussion 
(Chapter 6.4).
Although Aβ expression is mainly restricted to the brain, its precursor 
protein AβPP is ubiquitously expressed in mammalian cells with a broad 
tissue distribution (Fardilha et al., 2007). In addition to cerebral cortical 
neurons, AβPP has also been detected in other neural cells (neurons 
and satellite glial cells of the dorsal root, enteric and trigeminal ganglia, 
and the adeno- and neurohypophysis), as well as in extraneuronal cells 
(megakaryocytes and adrenal gland cells) in samples from both AD patients 
and non-AD individuals (Selkoe et al, 1988; Arai et al., 1991). More recently, 
AβPP has also been reported in epidermal melanocytes and melanoma 
cells (Quast et al., 2003), thyroid cells and keratinocytes (Pietrzik et al., 
1998; Schmitz et al., 2002), human sperm (Fardilha et al., 2007), malignant 
tumors such as oral squamous cell carcinoma (Lin et al., 2002), and neuronal 
(Nakagawa et al., 1999) and gastrointestinal (Meng et al., 2001; Hansel et 
al., 2003) carcinoma cells.
2.3.4. Alzheimer’s disease (Ad), Aβ, and neuroinflammation
The previously mentioned extracellular accumulation of Aβ as amyloid 
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plaques is one of the histopathological hallmarks of AD. During the last 15 
years, numerous inflammatory mediators have been observed (Akiyama 
et al., 2000), including complement proteins (Eikelenboom and Veerhuis, 
1996). Only after it was accepted that the brain was not an immunologically 
isolated organ (Hickey and Kimura, 1988), has increasing information based 
on animal models and clinical studies accumulated about the involvement 
of inflammation in AD pathogenesis. The chronic inflammatory response 
in AD is closely associated with amyloid plaques (Rogers et al., 2002), and 
locally induced by Aβ without any apparent influx of leukocytes from the 
circulation (Rogers et al., 1992; Eikelenboom et al., 2000). A long list of 
inflammatory mediators such as complement proteins, cyto- and chemokines, 
cyclooxygenases, coagulatory and fibrinolytic proteins, β-integrins, and 
free radicals have been encountered in AD (Eikelenboom and Stam, 1982; 
Akiyama et al., 2000). However, at present none of these factors, synthesized 
by neurons, astrocytes, and microglia (Bergamaschini et al., 2001; Veerhuis 
et al., 1999), is considered to be a principal factor in AD pathophysiology 
(Akiyama et al., 2000).
In in vitro studies, Aβ peptide induces an inflammatory cascade with the 
expression of cytokines and CD40 in human vascular cells (Suo et al., 1998), 
in close proximity to amyloid plaques (Rogers et al., 2002). Further, in familial 
British dementia (FBD) and familial Danish dementia (FDD), deposition of 
the cerebrovascular amyloid proteins ABri and ADan, respectively, associates 
with complement activation using both the classical and alternate pathways 
(Rostagno et al., 2002) (Ghiso et al., 2000; Holton et al., 2002). These forms of 
dementia carry striking neuropathological similarities with AD, in particular 
with CAA (Rostagno et al., 2002).
Complement proteins are commonly encountered in parenchymal Aβ 
deposits (senile plaques), including C3d (McGeer et al., 1989) and membrane 
attack complex (Akiyama et al., 2000). Aggregated Aβ is able to activate 
complement in an antibody-independent fashion, by binding to C1q 
(Yasojima et al., 1999; Rogers et al., 2002). Complement is also activated in 
human brain tissue in association with infarction (Lindsberg et al., 1996) 
and immunological neurological disease (Sanders et al., 1986; Compston 
et al., 1989), as well as in the cerebrospinal fluid following subarachnoid 
hemorrhage (Lindsberg et al., 1996).
2.3.5. origin of cAA
The origin of the amyloid proteins, especially fibril protein Aβ, deposited in 
the cerebral blood vessels, is poorly understood. Different theories about the 
origin of CAA (Table 6) have been proposed (Revesz et al., 2003).
According to the systemic theory, the cerebrovascular Aβ deposits are derived 
from the circulation, like the amyloid deposits in systemic amyloidosis. 
This is supported by the observation that AβPP is expressed by most cell 
types in the body, and that AβPP is detectable in plasma (Zlokovic, 2002). 
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The two-directional receptor-mediated transport of Aβ across the BBB 
and its exchange between the CNS, blood, and CNF, in part determines 
the concentration of Aβ in the CNS. Several receptors have been implied 
in this process such as RAGE, LRP-1, scavenger receptor, and the megalin 
receptor (Zlokovic, 2002). RAGE-mediated transport of Aβ takes place 
at the luminal side of the BBB, facilitating Aβ transport in the luminal to 
abluminal direction, and allowing a significant influx of Aβ into the brain 
(Zlokovic, 2002). In contrast, LRP-1 receptor-mediated transport is initiated 
abluminally (i.e. CNS side) and thus has a role in eliminating Aβ from the 
cerebral interstitial fluids (Zlokovic, 2002). One of the factors modulating 
this process is APOE, which is a ligand of LRP-1. APOE is a confirmed risk 
factor for AD (Polvikoski et al., 1995), but interestingly, it is also a risk factor 
for CAA. The arguments against a blood-borne source of cerebrovascular 
Aβ is firstly that morphological Aβ is initially detectable in the abluminal 
(brain side) basement membrane of blood vessels (Yamaguchi et al., 1992). 
Secondly, trangenic mice overexpressing the 99-amino-acid C-terminal 
region of the human AβPP in multiple tissues, including exceptionally high 
levels in the plasma, showed no CNS changes up to age 29 months (Fukuchi 
et al., 1996).
Table 6. Theories on the origin of CAA.
Name of the 
theory
Source of Aβ Mediated by Arguments against*
Systemica a) Circulation, across the BBB
b) CSF
-several receptors at BBB: 
e.g. RAGE at the luminal 
side and
LRP-1 at the abluminal 
(brain) side 
-Aβ is first detectable at the 
abluminal (brain) side
-AβPP transgenic mice show 
no CNS changes at a very 
advanced age
Vascularb Local production by 
cerebrovascular cellular 
elements, e.g. smooth muscle 
cells
-Aβ deposits have been 
detected in capillaries
-larger arteries are less 
affected than the smaller 
vessels
Drainagec Neurons in the CNS -draining and concomitant 
deposition of Aβ along the 
periarterial perivascular 
spaces 
CAA = cerebral amyloid angiopathy; Aβ = amyloid β-protein; BBB = brain blood barrier; CSF = cerebrospinal 
fluid;  
RAGE = receptor for advanced glycation end-products; AβPP = amyloid β precursor protein; CNS = central 
nervous system; LRP = low-density lipoprotein receptor-related protein.
*See text: Review of the Literature, Chapter 2.3.5.
aZlocovic, 2002.
bFrackowiak et al., 1994.
cWeller et al., 1998.
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Another source of Aβ in CAA could be the CSF, since Aβ is found in 
the CSF in both individuals with normal cognition and in AD patients (Ida 
et al., 1996; Ghiso et al., 1997). An argument supporting this hypothesis of 
origin is that in CAA small arteries are more commonly affected than the 
larger blood vessels in the subarachnoid space (Revesz et al., 2003).
The vascular hypothesis suggests that Aβ is derived from cerebrovascular 
cellular elements. Morphologically, Aβ has been shown to be closely associated 
with cerebrovascular smooth muscle cells (Frackowiak et al., 1994). Isolated 
cerebral microvessels and meningeal blood vessels are able to produce Aβ 
(Kalaria et al., 1996). Aβ is also expressed by smooth muscle cells, pericytes, 
and endothelial cells (Burgermeister et al., 2000). Some arguments against 
the vascular hypothesis are that Aβ deposits have also been detected in 
capillaries, and that larger arteries with several layers of smooth muscle cells 
are less affected than smaller vessels (Weller et al., 1998).
The drainage hypothesis proposes that Aβ, produced primarily by CNS 
neurons, is drained along the periarterial perivascular spaces of the brain 
parenchyma and leptomeninges, and that CAA occurs due to Aβ deposition 
along these drainage pathway vessels (Weller et al., 1998). Degenerative 
vascular changes, which commonly affect aged individuals, could have a 
deleterious effect on the perivascular flow of interstitial fluid and be a factor 
in the vascular deposition of Aβ. The presence of CAA in transgenic animal 
models of AD, in which AβPP is expressed by neurons, could also support the 
drainage hypothesis (Burgermeister et al., 2000; Van Dorpe et al., 2000).
Some of the amyloid peptides implicated in familial CAAs, such as ACys, 
ATTR, and AGel, deposit in systemic organs, supporting the systemic theory. 
In both FBD and FDD, the origin of the amyloid plaques is not known. 
BriPP mRNA is expressed in normal human brain (Vidal et al., 1999), 
indicating possible local production. On the other hand, ABri is also found 
in the circulation and in the tissues (Ghiso et al., 2001) and thus may also 
be peripherally produced (Revesz et al., 2003).
2.3.6. Hereditary forms of cAA
The familial forms of CAA are rare. The most important hereditary condition 
associated with CAA is hereditary AD, which is caused by mutations in 
several genes. Hereditary AD is inherited in an autosomal dominant manner 
with almost complete gene penetrance in only about 5% of all cases (Revesz 
et al., 2003).
In the gene for AβPP, which is present on chromosome 21, several 
missense mutations have been detected. These mutations are located 
within or just outside the region encoding the Aβ peptide, near one of the 
secretase cleaving sites. These mutations exert their pathogenic effect through 
different mechanisms and often have characteristic clinical and pathological 
phenotypes. Severe CAA can also be associated with AD in cases where 
there are mutations in the PS-1 and PS-2 genes, or in the gene for cystatin-C, 
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with the latter leading to HCHWA-I. Leptomeninges and meningeal vessels 
can also be affected by familial TTR amyloidosis (Benson, 1996), especially 
prominent in the Hungarian (D18G) and Ohio (V30G) mutations (Garzuly 
et al., 1996; Petersen et al., 1997; Vidal et al., 1996). In AGel (Kiuru, 1998a) 
and prion protein amyloidosis (Ghetti et al., 1996), CAA has also been 
described. In familial British (FBD) and Danish (FBD) dementia, severe 
CAA is one of the pathological hallmarks. In these diseases, the genetic 
abnormality results in elongation of the 266-amino-acid wildtype precursor 
protein designated as BRI-PP. This precursor protein is processed, resulting 
in the secretion of mutated C-terminal peptides that are 34 amino acids in 
length (Kim et al., 1999). The amyloid peptides designated as ABri in FBD, 
and ADan in FDD, have unique 12-amino-acid C-terminal sequences that 
have allowed for the generation of “mutation-specific” antibodies, which 
exclusively recognize either ABri or ADan (Revesz et al., 2003).
2.3.7. tau protein and neurodegeneration
The other pathogenomic lesion of AD, described already by Alois Alzheimer 
and the main constituent of the intraneuronal neurofibrillar tangles and 
extraneuronal neurofibrillary threads, is the microtubule-associated protein 
tau (Grundke-Iqubal et al., 1986a). These filamentous structures have also 
been encountered in other neurodegenerative diseases such as progressive 
supranuclear palsy, corticobasal degeneration, Pick’s disease, argyrophilic 
grain disease, and inherited frontotemporal dementia and parkinsonism 
linked to chromosome 17 (Wilhelmsen et al., 1994; Baker et al., 1999; Fallin, 
2001; Goedert, 2005). In intracellular neuronal deposits, tau protein is mainly 
in the phosphorylated, toxic form (Grundke-Iqubal et al., 1986b) as paired 
helical filaments. In adult human brain, tau exists in six major isoforms, 
which are generated by alternative splicing of exons 2, 3 and 10 of the tau 
gene (Goedert, 2005). In AD, the neurofibrillar tangles contain all six major 
tau isoforms. In contrast, in for example progressive supranuclear palsy, only 
4-repeat tau is found. Phosphorylated tau also accumulates in the inclusion 
bodies of diseased muscle cells in sporadic inclusion body myositis (Askanas 
et al., 1994). In addition, tau epitopes have been detected in oculopharyngeal 
and Becker muscular dystrophy, dermatomyositis, central core disease, 
neurogenic atrophy, and in the recovery phase of an attack of malignant 
hyperthermia (Lubke et., 1994). In animals, tau is widely expressed and can 
be found in the heart, skleletal muscle, lung, kidney, testis, adrenal gland, 
stomach, and liver (Ashman et al., 1992; Gu et al., 1996).
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2.4. Hereditary gelsolin (AGel) amyloidosis
2.4.1. definition, clinical characteristics, and  
    histopathological findings
Hereditary gelsolin (AGel) amyloidosis is an autosomal dominant form of 
systemic amyloidosis originally reported from Finland (Meretoja, 1969), 
and thereafter from several European countries, North America and Japan 
(Conceicao et al., 2003; Kiuru, 1998; Makishita et al., 1996; Stewart et al., 
2000). The most prominent clinical features, after onset in the thirties, are 
slowly progressive corneal lattice dystrophy, cranial neuropathy, and cutis 
laxa. AGel amyloidosis is caused by a G654A, or rarely, G654T mutation 
in the gene coding for gelsolin on chromosome 9 (Levy et al., 1990; de la 
Chapelle et al., 1992). Neurological involvement in AGel amyloidosis ranges 
from cranial and peripheral to autonomic nerves and the central nervous 
system (Meretoja, 1969; Kiuru et al., 1994; Kiuru et al., 1999; Rosenberg 
et al., 2001). The most common neurological feature is slowly progressive 
cranial neuropathy with onset in the forties, and predominant facial and 
lower cranial nerve involvement that can cause severe bulbar paresis at 
old age. Some patients who were originally published as atypical bulbar 
amyotrophic lateral sclerosis (Klaus et al., 1959) were later shown to carry 
the G654T gelsolin gene defect (de la Chapelle et al., 1992). Autonomic and 
cerebral involvement with AGel deposition is usually less significant (Akiya 
et al., 1996; Kiuru, 1998). Although the disease may cause ataxia of gait and 
minor (mainly sensory) somatic nerve involvement (Kiuru, 1998), it has not 
previously been shown to be lethal.
2.4.2. synthesis, structure, and function of gelsolin
Gelsolin is the principal actin-severing protein in mammalian leukocytes, 
platelets, and other cells with powerful effects on actin (Janmey et al., 1985; 
Kwiatkowski and Yin, 1987). In addition to the cytoplasmic form, gelsolin 
also appears in the plasma wherein the majority is derived from muscle 
(Kwiatkowski et al., 1988). Both forms of gelsolin are encoded by a single 
gene (Kwiatkowski and Yin, 1987). In vitro studies have shown that the 
G654A and G654T gelsolin gene mutations do not interfere with the normal 
actin-modulating function of intracellular gelsolin. Moreover, the aberrant 
processing of secreted mutant gelsolin to AGel amyloid precursor takes 
place in a gelsolin-negative background, suggesting that the symptoms are 
caused by the accumulation of amyloid derived from secreted plasma gelsolin 
in the tissues (Kangas et al., 1999) rather than the functional aberration 
of cytoplasmic gelsolin. In specific tissues, the larger precursor protein 
is cleaved first by furin, a proprotein convertase (Chen et al., 2001), and 
thereafter by a MT1-MMP-like protease (Page et al., 2005) to yield the 
amyloidogenic peptides.
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2.5. Medin (AMed) amyloidosis
2.5.1. definition and histopathological findings
Aortic medial or medin (AMed) amyloidosis is a very common local 
form of an old age-associated amyloid disorder (Schwarz P. New patho-
anatomic observations on amyloid in the aged. Fluorescence microscopic 
investigations. In: Mandema E, Ruinen L, Scholten JH, Cohen AS, editors. 
Amyloidosis. Amsterdam: Excerpta Medica, 1968. pp. 400-4155; Battaglia 
and Trentini, 1978; Cornwell et al., 1982; Cornwell et al., 1983). It occurs in 
virtually all individuals aged ≥ 60 years (Haggqvist et al., 1999; Reches and 
Gazit, 2004). AMed amyloid is also found in other arteries, mainly in the 
upper part of the body, including the temporal and basilar arteries (Peng et 
al., 2002; Peng et al., 2005). In AMed amyloidosis, the individual amyloid 
deposits are small and situated in close association to the internal elastic 
lamina (Peng et al., 2005). Interestingly, in giant cell arteritis of temporal 
arteries, AMed amyloid is found within the inflammatory exudate in the 
blood vessel wall (Peng et al., 2002).
2.5.2. synthesis, structure, and function of lactadherin
Medin, a 50-amino-acid internal fragment of the 364-amino-acid precursor 
protein lactadherin, also called milk fat globule protein or BA46 (Couto et al., 
1996, Andersen et al., 2000), is the main amyloid constituent of aortic medial 
amyloid. The amyloid fibril protein, called medin, corresponds to positions 
245-294 of lactadherin (Haggqvist et al., 1999). The functions of lactadherin 
are poorly understood. Lactadherin is expressed by breast epithelial cells and 
thus occurs in milk. It has also been proposed to provide protection against 
rotavirus infection (Newburg et al., 1998) and is suggested to have properties 
important for the coagulation system (Peng et al., 2002). Apart from breast 
epithelial cells, lactadherin is expressed in several kinds of cells including 
smooth muscle cells (Peng et al., 2005). Thus, medin synthesis is suggested 
to be local, supported by the finding that although both water-soluble and 
-insoluble lactadherin is found when analyzing proteins extracted from 
amyloid-rich aortic media, only insoluble medin could be detected in the 
amyloid fraction (Peng et al., 2005).
3. THERAPY
After introduction of the term “amyloid” into medical literature, more than 
a century elapsed until any therapy was available for amyloid diseases. The 
first steps were taken in AA (inflammation-associated) amyloidosis in which 
it was noted that when the infective focus was removed, the development 
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of amyloid accumulation could be hindered (Waldenström, 1976). In 1986, 
Zemer showed that in familial Mediterranean fever colchicine is able to, 
apart from preventing attacks of the disease, hinder the development of AA 
amyloidosis which is a late complication of the disease (Zemer et al., 1986). 
An evaluation of the effects of amyloid disease therapy has been possible 
since 1988 when Hawkins and Pepys introduced 123I-SAP (serum amyloid 
P–component) scintigraphy as a clinical method to visualize the presence of 
amyloid in organs (Hawkins et al., 1988). In 1991, Holmgren introduced liver 
transplantation as a treatment for hereditary TTR amyloidosis (Holmgren 
et al., 1991). Since 1996, remarkable advances in medical therapies for AL 
amyloidosis have also taken place (Skinner et al., 1996).
Several compounds have been investigated for their usefulness as 
medical therapies for amyloid diseases. Logical targets for therapy would 
focus on common amyloid features such as SAP binding, the presence 
of the glycosaminoglycan perlecan, and the fibrillar structure of amyloid 
(Buxbaum, 2004). Alternative therapeutic targets could utilize specific 
features of individual amyloid proteins. 
SAP, a protein associated with all amyloids, is able to inhibit proteolysis 
of amyloid fibrils in vitro, and slows AA amyloid deposition in mice devoid 
of SAP (Botto et al., 1997). In AL amyloidosis, a specific inhibitor of SAP 
binding that reduces SAP levels has been administered in a phase I/II 
study. This compound was quite safe in the initial report (Pepys et al., 
2002), but its efficacy and safety in humans is not yet known (Buxbaum, 
2004). Anionic sulfonates, such as glycoaminoglycans, may also be used 
in order to prevent amyloid formation (Kisilevsky et al., 1995), and they 
have been shown to be active in the treatment of murine inflammation-
induced AA amyloidosis (Kisilevsky and Szarek, 2002; Kisilevsky et al., 
2007). Transgenic mice carrying a mutant human Aβ protein precursor 
develop amyloid plaques in their brains, analogous to those seen in human 
AD. Promising experiments actively or passively immunizing these mice 
against the Aβ 1-42 peptide, resulted in shrinking of the plaques in the 
CNS (Janus et al., 2000; Schenk et al., 1999). A vaccine trial with the same 
immunogen was initiated in human patients with advanced AD, but was 
stopped because some of the participants developed evidence of severe CNS 
inflammation (Nicoll et al., 2003). An immunogenic approach targeting 
AL has also been investigated in mice (Hrncic et al., 2000), and animal 
models of immunization against selected TTR mutants have recently been 
reported (Terazaki et al., 2006).
In vitro, Aβ fibril formation has been inhibited by preventing the β sheet 
conformation by peptides that bind to Aβ (Soto et al., 1996). In vitro studies 
have also demonstrated that several nonsteroidal anti-inflammatory drugs 
and structurally similar compounds are able to inhibit TTR-amyloid fibril 
formation, based on these drugs complexing with TTR which leads to the 
stabilization of the tetrameric conformation of TTR. In addition, several 
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small molecules that inhibit TTR fibril formation have been identified or 
synthetized (Klabunde et al., 2000; Hammarstrom et al., 2003). Some of 
them have even been tested in transgenic mouse models (Buxbaum, 2004). 
These molecules include genistein and chromium (III) ion. Genistein, the 
major isoflavone natural product of soy, has been reported to be safe for 
human consumption and to reduce in vitro fibril formation of wildtype 
TTR, and the Val50Met and Val122Ile TTR variants (Green et al., 2005). 
The chromium (III) ion increases the in vitro binding capacity of thyroxin 
(T4) to the wildtype and Val30Met variant of TTR, thus suppressing amyloid 
fibril formation (Sato et al., 2006).
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AIMS OF THE STUDY
The aims of the present study were to:
1. Investigate the frequency of SSA and CAA in an elderly Finnish population 
(I, II, III)
2. Investigate health-associated and genetic risk factors for SSA and CAA 
(I, II, III)
3. Study the possible association between SSA and CAA (III)
4. Identify possible new amyloid-associated proteins in SSA, CAA, and 
AGel amyloidosis (I, II, IV)
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MATERIALS AND METHODS: 
1. SUBJECTS
1.1. Vantaa 85+ study protocol and participants (I, II, III)
The Vantaa 85+ study included all persons aged 85 years or more and 
living in the city of Vantaa (Southern Finland) on April 1, 1991. Of the 601 
eligible subjects, 553 participated in the study, while most of the remaining 
individuals died before they could be examined. The clinical follow-up studies 
were carried out in 1994, 1996, 1999, 2001, and, 2003. The present study is 
based on the results of consented post mortem examinations, performed 
in 51% of the Vantaa 85+ study material. This autopsy rate is worldwide 
the second highest among all prospective population-based studies with 
neuropathological examination of the subjects (Zaccai et al., 2006). Thus 
far, the study material has yielded several publications, the most notable of 
which are presented in Table 7.
1.1.1. ssA study (i)
The SSA study (I) included 256 subjects ≥ 85 years of age, ranging from 
85.1-105.6 years (mean 92.5 years), from whom both histological myocardial 
specimens and blood samples were available. 84% (214/256) of the subjects 
were females and 16% (42/256) were males.
1.1.2. cAA study (ii)
The CAA study (II) was based on post mortem specimens from 74 
individuals ≥ 95 years old, with ages ranging from 95.0-105.6 years (mean 
96.6), including all individuals in whom the required specimens from five 
brain areas for CAA diagnostics were available. 82% (61/74) were females 
with ranging from 95.1-105.6 years (mean 96.9), while 18% (13/74) were 
males ranging from 95.0-98.7 years (mean 95.6). 
1.1.3. Association between ssA and cAA (iii)
Association between SSA and CAA was studied on all 63 individuals, in 
whom both the myocardial and cerebral cortical specimens were available. 
The age range of this population was 95-105.6 years (mean 98). 84% (53/63) 
of the subjects were females whereas 16% (10/63) were males.
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Table 7. A list of selected publications on the Vantaa 85+ Study material.
Authors Title Publication
Genetic risk factor studies
Enattah et al. Genetic variant of lactase-persistent C/T-13910 is 
associated with bone fractures in very old age
J Am Geriatr Soc 2005
Myllykangas et al. Chromosome 21 BACE2 haplotype associates with 
Alzheimer’s disease: a two-stage study.
J Neurol Sci 2005
Lambert et al. Contribution of APOE promoter polymorphisms to 
Alzheimer’s disease risk.
Neurology 2002
Myllykangas et al. ApoE epsilon3-haplotype modulates Alzheimer beta-
amyloid deposition in the brain.
Am J Med Genet 2002
Myllykangas et al. Association of lipoprotein lipase Ser447Ter 
polymorphism with brain infarction: a population-
based neuropathological study.
Ann Med 2001
Baker et al. No association between TAU haplotype and 
Alzheimer’s disease in population or clinic based 
series or in familial disease.
Neurosci Lett 2000
Juva et al. Apolipoprotein E, cognitive function, and dementia 
in a general population aged 85 years and over.
Int Psychogeriatr 2000
Myllykangas et al. Cardiovascular risk factors and Alzheimer’s disease: 
a genetic association study in a population aged 85 
or over.
Neurosci Lett 2000
Myllykangas et al. Genetic association of alpha2-macroglobulin with 
Alzheimer’s disease in a Finnish elderly population.
Ann Neurol 1999
Sulkava et al. APOE alleles in Alzheimer’s disease and vascular 
dementia in a population aged 85+.
Neurobiol Aging 1996
Polvikoski et al. Apolipoprotein E, dementia, and cortical deposition 
of beta-amyloid protein.
N Engl J Med 1995
Other epidemiological studies
Barkhof et al. The significance of medial temporal lobe atrophy: a 
postmortem MRI study in the very old.
Neurology 2007
Rastas et al. Atrial fibrillation, stroke, and cognition: a 
longitudinal population-based study of people aged 
85 and older.
Stroke 2007
Polvikoski et al. Incidence of dementia in very elderly individuals: 
a clinical, neuropathological and molecular genetic 
study.
Neuroepidemiol
2006
Rastas et al. Association between blood pressure and survival over 
9 years in a general population aged 85 and older.
J Am Geriatr Soc 2006
Rastas et al. 
 
Association of apolipoprotein E genotypes, blood 
pressure, blood lipids and ECG abnormalities in a 
general population aged 85+.
BMC Geriatr 2004
Polvikoski et al. Prevalence of Alzheimer’s disease in very elderly 
people: a prospective neuropathological study.
Neurology 2001
Rahkonen et al. Delirium in the non-demented oldest old in the 
general population: risk factors and prognosis.
Int J Geriatr Psychiatry 
2001
Juva et al. APOE epsilon4 does not predict mortality, cognitive 
decline, or dementia in the oldest old.
Neurology 2000
Päivärinta et al. The prevalence and associates of depressive disorders 
in the oldest-old Finns.
Soc Psychiatry 
Epidemiol 1999
Kiljunen et al. Depression measured by the Zung Depression Status 
Inventory is very rare in a Finnish population aged 85 
years and over.
Int Psychogeriatr 1997
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1.1.4. Blood samples (i, ii)
The frozen blood samples for DNA testing were available from 86% of the 
entire study population (517/601). All 256 participants in study I, and all 63 
participants in study III, were genetically tested. In study II, a blood sample was 
available from 96% (71/74) of the neuropathologically studied individuals.
1.2. Case report on AGel amyloidosis (IV)
The report on advanced Gelsolin amyloidosis describes a 78-year old male 
referred to the Department of Neurology at Helsinki University Central 
Hospital in Helsinki, Finland for the evaluation of progressive imbalance. 
After one year, the patient became bedridden, had respiratory and subsequent 
gastrointestinal infections, and died at the age of 79.
1.3. Medin study
The occurrence of medin in CAA was studied in histological cerebral cortical 
samples from ten individuals with clinical AD and seven controls with 
normal cognition.
2. CLINICAL AND POST MORTEM INVESTIGATION
2.1. Vantaa 85+ study (I, II, III)
2.1.1. interview and clinical examination of the subjects  
    (i, ii, iii)
The Vantaa 85+ study protocol was based on interviews of the subjects 
on several medical, social, economical and health-associated parameters, 
as well as clinical examinations including a thorough neurological study 
(Polvikoski et al., 1995). 
The clinical data was obtained in the baseline study in 1992 and several 
follow-ups (Myllykangas et al., 2001). In this study, several health-associated 
factors were included. Subjects were classified as having diabetes mellitus 
(DM; I) if they used blood glucose lowering medication or insulin, and 
hypetension (HT; I) if they used any blood pressure lowering medication. 
The BMI values (body mass index, weight divided by height squared; I) were 
classified into five categories: 1 ≥ 32; 2 = 28-31; 3 = 19-27; 4 = 15-18; 5 ≤ 14. 
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If an exact measurement was not possible, the BMI category was estimated. 
The clinical diagnosis of dementia (II, III) was performed according to the 
guidelines of the American Psychiatric Association (1987) and included 
memory, behavior, emotional, and social function tests. The clinical diagnosis 
of AD (II, III) was based on the NINCDS-ADRDA criteria (McKhann et al., 
1984), which is mainly based on the exclusion of other clinically significant 
causes of dementia, e.g. cerebrovascular disease or Parkinsonism. In the 
present study, the clinical diagnosis of dementia was divided into four 
categories: no dementia, AD, vascular dementia, or other dementia.
The data obtained during autopsy included heart weight measurements 
(I), and the diagnosis of myocardial infarctions (MIs; I) using the naked 
eye and subsequent confirmation by histological examination. Both acute 
infarctions and old scars were noted. The histopathological diagnosis of AD 
(II, III) was set using the National Institute and Reagan Institute (NIA-RI) 
criteria (The National Institute on Aging and Reagan Institute Working Group 
on Diagnostic Criteria for the neuropathologic assessment of Alzheimer’s 
Disease) (Hyman and Trojanowski, 1997; Geddes et al., 1997), and the 
modified NIA-RI criteria as described previously (Polvikoski et al., 2001).
2.1.2. Autopsy with neuropathological examination (ii, iii)
By December 2000, 306 autopsies (306/601; 51%) with neuropathological 
examination were performed. In the SSA study (I), the final number of 
acceptable cases was 256, representing 46% (256/553) of the Vantaa 85+ 
study population. The CAA study (II) included 74 autopsied individuals, 
representing 97% (74/76) of all individuals ≥95 years of age. The SSA/CAA 
study (III) was comprised of all 63 autopsied individuals aged 95 years or 
more, from which both myocardial and histological autopsy samples and a 
blood sample for APOE genotyping were available. 
At the general autopsy, the heart weight was measured (I), the prescence 
of amyloid was studied (I), and the diagnosis of myocardial infarctions 
(MIs) was made with the naked eye (I). Both acute MIs and old scars were 
noted, and their prescence was confirmed by histological examination. 
One standard specimen of the interventricular septum of the heart was 
taken, and two to four additional samples if the macroscopic finding was 
not normal. One single sample was taken in 65% (167/256), two samples in 
26% (66/256), three samples in 8% (20/256), four samples in 0.8% (2/256) 
and five samples in 0.4% (1/256) of the study subjects, with a mean of 1.5 
samples for one individual. The specimens were fixed in 4% phosphate-
buffered formaldehyde solution. The histological diagnosis of MIs was 
based on hematoxylin-eosin stained tissue sections. SSA was diagnosed 
by detecting amyloid on the Congo red stained, five µm-thick sections, by 
identifying the typical red–apple green birefringence of amyloid in polarized 
light. Based on Congo red, the amount of amyloid in the myocardium was 
semi-quantitatively graded (Table 8a): 0 = no amyloid; 1 = small amounts 
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of amyloid in the vascular walls or between the myocardial cells; 2 = clearly 
detectable areas of amyloid in several visual fields, including vascular 
deposits; 3 = large amounts of amyloid.
Table 8a. Grading the severity of SSA.
Congo red staining in the myocardium Grade of SSA = Severity of SSA
Negative 0 No
Positive reaction in occasional blood vessels or in 
small areas between the cardiac myocytes
1 Mild
Clearly detectable reaction in several regions 2 Moderate
Strong reaction in large areas 3 Severe
Note: The diagnosis is based on red-green birefringence in polarized light in a light microscope.
For the CAA study (II), the brains were fixed in 4% phosphate-buffered 
formaldehyde. Five tissue samples from the frontal, temporal, and parietal 
lobes, hippocampus, and cerebellum were embedded in paraffin and stained 
with histological Congo red, hematoxylin and eosin, and iron stains. Grading 
of the severity of CAA was performed following the guidelines presented 
by Ellis et al. (Ellis et al., 1996). Eight µm-thick paraffin sections from 
the frontal, parietal, temporal, cingular, and cerebellar cortex were stained 
with Congo red and analyzed in polarized light. The Congo red-positive 
small leptomeningeal and cortical blood vessels were identified and their 
percentage of all respective vessels was estimated (Table 8b). The borders 
in the samples were set as follows: 0% for no CAA, 1-29% for weak (mild 
CAA, grade 1), 30-59% for moderate (moderate CAA, grade 2), and 60-100 
% for strong positivity (severe CAA, grade 3). In severe CAA, amyloid 
extended into the surrounding brain parenchyma. A general score of 
CAA severity (ranging from 0-3) for each individual patient was given, by 
taking the average of four examined cerebral brain regions (Table 5). The 
cerebellar samples were not included to this score, as these severity scores 
were later compared with the cognitive status of the subjects. The brains 
were also studied for cortical or subcortical infarctions, older ischemic 
scars, or hemorrhages for all cerebral areas mentioned above. The ischemic 
lesions were diagnosed using hematoxylin and eosin stained five µm-thick 
sections. Further, to confirm the diagnosis of past hemorrhage, the presence 
of iron stored in macrophages was evaluated on five µm-thick sections using 
routine histological iron stain. In this staining, the amounts of blue-stained 
macrophages and erythrophages with brown cytoplasm were counted, and 
based on this the grade of hemorrhage (0-3) was assessed. Small lacunar 
lesions without any tissue reaction were not considered, as it is very difficult 
to differentiate them from artifactual post-mortal alterations. 
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Table 8b. Grading the severity of CAA*.
% Congo red-positive blood vessels of small lepto- 
meningeal and cortical blood vessels in a brain region
Grade of CAA = Severity of CAA
0 0 No 
1-29 1 Mild
30-59 2 Moderate
60-100 3 Severe
Note: The diagnosis is based on red-green birefringence in polarized light in a light microscope.
*The methods follow the guidelines presented by Ellis et al.1996. In addition to the cortical samples 
(frontal, temporal, and parietal lobes, cingulate gyrus), cerebellum was also studied. An individual 
CAA severity score was obtained by taking the average of the four cortical regions.
In study II, the neuropathological diagnosis of AD (II) was set using the 
modified NIA-RI criteria (Polvikoski et al., 2001). The original NIA-RI criteria 
for neuropathological AD consist of a combination of the CERAD protocol 
(Mirra et al., 1991) and the Braak staging system (Braak and Braak, 1991). 
The CERAD protocol is based on estimation of the frequency of neuritic 
plaques in the cerebral cortex, while Braak staging rests on a hypothesis of 
progression of neurofibrillar pathology in the brain according to different 
stages of the disease. The modified classification system (Polvikoski et al., 
2001) creates low and high probability groups for AD. Individuals with 
moderate or frequent neuritic plaques in the CERAD classification, and 
with stages III to VI in the Braak staging system, were classified as high 
probability cases for neuropathological AD and categorized as “NIA-RI 
AD” cases. However, both original and modified criteria can only yield a 
possibility and not a definite diagnosis for AD.
2.2. AGel amyloidosis (IV)
2.2.1. clinical examination, laboratory tests, and radiological  
    and neurophysiological studies (iV)
In this study (IV), amyloidosis was diagnosed when the patient was in 
his fifties. Laboratory studies performed during admission to the hospital 
included blood cell counts, erythrocyte sedimentation rate, glucose, protein 
electrophoresis, electrolytes, creatinine, α2-globulin fraction, creatine kinase, 
aldolase, aspartate and alanine transaminases, γ-glutamyltransferase, folic acid, 
vitamin B12, syphilis serology, and ECG. Radiological magnetic resonance 
imaging (MRI) studies on brain, spinal cord, and lower leg skeletal muscles 
were performed with a 1.5 T high-field unit (Siemens Vision, Erlangen, 
Germany). Neurophysiological tests included motor nerve conduction, 
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sensory evoked potential (SEP), needle electromyography (EMG), median 
nerve stimulation, and quantitative sensory testing (QST).
2.2.2.Autopsy with neuropathological examination (iV)
The brain and spinal cord, peripheral nerve and skeletal muscle specimens 
were fixed in 4% phosphate-buffered formaldehyde and embedded in 
paraffin, and for sural nerve specimens, also in Epon. Congo red was used 
to detect amyloid, and immunohistochemistry (IHC) was carried out on 
five µm-thick tissue sections and processed using the avidin-biotin complex 
method, to characterize amyloid proteins and associated components. 
2.3. Staining methods
2.3.1. Histological staining methods
2.3.1.1. Congo red
Congo red staining was performed using a modified Puchtler’s staining 
method and Congo red purchased from Merck KGaA, Darmstadt, Germany 
(Kongorot C.1.22120) on five μm- (heart) or eight μm- (brain) thick paraffin-
embedded tissue sections. 50 ml of saturated Congo red solution was made 
by adding the dye to 50 ml of saturated NaCl (in 80% alcohol) solution and 
0.5 ml of 1% NaOH. The saturated dye solution was stirred and filtered. Next, 
the paraffin-embedded tissue sections were deparaffinized in the typical 
manner, rehydrated, and placed in Mayer’s hematoxylin for 10 minutes. 
After washing twice in distilled water, the sections were incubated for 15 
min in the saturated NaCl solution followed by saturated Congo red solution 
for 20 minutes. Thereafter, the slides were rinsed quickly in 96% ethanol, 
absolute alcohol, and xylene solutions. In addition to staining tissue slides of 
the study material, positive and negative control slides were always stained 
simultaneously.
2.3.1.2. Other stainings
The routine hematoxylin and eosin staining, done using an automated 
staining device (Labvision), was performed in order to make a morphological 
diagnosis of the nervous and muscle tissue. A routine connective tissue 
staining (Herovichi) applied by the staining device was used to diagnose 
the fibrous scar tissue in the myocardium. A routine Fe++ staining was 
performed to diagnose recent or prior hemorrhages in the brain tissue.
2.3.2. immunohistochemistry (iHc)
Immunohistochemical staining methods were used to characterize amyloid 
and/or other proteins in brain and myocardial tissue. Immunohistochemical 
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stainings were performed on five µm-thick paraffin sections on all samples, 
which demonstrated positive reactivity under polarized light after staining 
with Congo red. The serial sections were processed by the avidin-biotin 
complex method using Vectastain Avidin-Biotin kit according to the 
manufacturer’s instructions. For control of specificity, normal rabbit serum 
(Aβ, C3d, TTR), phosphate buffered saline (Aβ), or goat IgG was used (C9). 
The antigens used are listed in Table 9.
2.3.3. double-staining with medin and congo red
A double-staining using medin and Congo red was performed on selected 
cases with severe CAA. Briefly, IHC using rabbit anti-medin antibody (to 
lactadherin at positions 286-293; A172) was performed using normal goat 
serum for blocking (microwave, pH 6, primary antibody overnight in 4°C, 
visualization with DAB). After IHC, Congo red staining was carried out on 
the same slides. In the light microscope, the Congo red-positive areas showed 
red-green birefringence in polarized light whereas the structures that were 
reactive in the anti-medin IHC were detectable as brown granules.
2.4. Genetic analyses (I, II, IV)
2.4.1. candidate gene polymorphisms (i, ii)
Genetic polymorphisms in the following genes were analyzed by PCR-based 
methods as described earlier: angiotensin converting enzyme (ACE), alpha-2 
macroglobulin (α2M), apolipoprotein E (APOE), beta-amyloid cleaving 
enzyme2 (BACE2), lipoprotein lipase (LPL), low-density lipoprotein receptor-
related protein (LRP), prion protein, and tau (Myllykangas et al., 1999; Baker 
et al., 2000; Myllykangas et al., 2000; Nurmi et al., 2003; Myllykangas et al., 
2005; Myers et al., 2005).
2.4.2. ttr gene sequencing (i)
The gene for TTR was sequenced in six individuals with severe SSA (grade 
3) by amplifying the exons of the TTR gene by standard PCR methods. 
PCR products were purified using enzymatic ExoSAP treatment (USB 
Corporation, Cleveland, OH, USA) and sequenced using BigAnalyzed 
(Applied Biosystems). The sequence analysis was carried out using the 
Sequencer 4.5 Software (Gene Codes Corporation, Ann Arbor, MI, USA).
2.4.3. Genotyping of the exon 2 mutation in the ttr gene (i)
Genotyping of the exon 2 mutation in the TTR gene was performed in all 256 
samples by using the same PCR primers and conditions that were used for 
the sequencing of exon 2. The PCR product was digested with the restriction 
enzyme Msp I (New England Biolabs, Ipswich, MA, USA).
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2.4.4. APOE genotyping (I, II)
APOE genotyping was performed as described previously (Myllykangas et 
al., 2002). Because very advanced age may influence the relative frequency 
of different APOE genotypes and the risk for amyloidotic cerebral diseases, 
the frequencies of APOE alleles and genotypes in the very elderly subgroup 
(I, II) were first compared to another age group of the study population, 
i.e. those who died at the age of 85-94 years old (n=400). The frequency of 
the ε4 allele was slightly reduced in the oldest age group (12.7% vs. 17.1%), 
but this difference was not statistically significant. None of the alleles or 
genotypes of APOE differed significantly between these subgroups of the 
Vantaa 85+ study population.
2.4.5. Gelsolin gene analysis (iV)
Genetic testing for the gelsolin gene mutation was performed as described 
earlier (Paunio et al., 1992).
2.5. Statistical analyses (I, II, III)
The statistical analyses were performed using the SPSS for Windows version 
12.0.1 software. Differences between the groups (SSA+/SSA-, CAA+/CAA-, 
genetic polymorphisms, diabetes, hypertension, BMI category, smoking; 
dementia, dementia type; I, II, III) and interrelationships between the 
variables (CAA, APOE, and dementia; II) were analyzed with the Chi-
Squared or exact test for linear categorical variables. For continuous variables 
(age at death, heart weight; I), logistic regression analysis (I) or Student’s 
two-tailed t-test (age at death; III) was used. The association between 
genotype and SSA was studied by logistic regression, controlling for possible 
confounding effect of age and MI on (I). Correlation between the genotypes 
and severity of SSA (I) was conducted using the Chi-Squared or exact test 
for linear trend. P-values <0.05 were considered significant.
3. APPROVAL FOR THE STUDY
The Vantaa 85+ study was approved by the Ethics Committee of the Health 
Centre of the City of Vantaa. The Finnish Health and Social Ministry has 
approved the use of the health and social work records, and death certificates. 
Blood samples were collected only after the subjects or their relatives gave 
informed consent. The National Authority for Medicolegal Affairs has 
approved the collection of the tissue samples at autopsy as well as their use 
for research. A written consent for autopsy was obtained from the nearest 
relatives.
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RESULTS: 
1. FREQUENCY AND DISTRIBUTION OF SSA AND 
CAA (I, II, III)
1.1. Frequency of SSA (I)
1.1.1. Frequency of ssA in a population aged 85 years or  more (i)
Amyloid deposition in one or more of the Congo red stained myocardial 
specimens (Figure 1A,B; p.28) was detected in 25% (63/256) of the study 
(I) population. In all cases, the amyloid deposits showed a positive reaction 
in anti-TTR immunohistochemical stainings (Figure 1C). SSA was mild in 
78% (49/63), moderate in 11% (7/63), and severe in 11% (7/63). 
1.1.2.Frequency of ssA in a population aged 95 years or more (iii)
SSA was found in 37% (23/63) of individuals aged 95 years or more (III), 
and consisted of 19 women and four men.
1.1.3. distribution and morphology of ssA in the myocardium  
   (tanskanen et al., unpublished data)
Congo red positivity was observed in every specimen taken from the 
myocardium in almost all of the subjects (97%; 61/63) having SSA. Among 
individuals positive for Congo red in the myocardium, there was only 
one in whom amyloid was solely vascular. Out of the 62 individuals with 
parenchymal SSA, in 52% (32/62) vascular amyloid could be detected as 
well. Histologically, the amyloid distribution in the myocardium was patchy 
and haphazard. In the tissue sections, the TTR-based amyloid deposits 
were located between the preserved striated muscle fibers. Sometimes, 
but not always, they were located in proximity to fibrous scars (Figure 
1), acute infarctions, or blood vessels. In contrast, in the fibrous areas, the 
deposits were relatively small. Amyloid deposits were not associated with 
any particular anatomical region of the heart. In many cases of moderate 
or severe SSA, the myocardial cells showed increasing size and deformity of 
the nuclei, typical of chronic hypoxia. Occasionally, in a few of the control 
(Congo red negative) cases, minute reactivity in the anti-TTR IHC was 
observed.
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In the histological connective tissue (Herovichi), connective tissue staining 
(Figure 1D; p.28) was performed on 14 cases with moderate or severe 
SSA, and amyloid deposits could be readily distinguished as light orange 
homogenous material, clearly distinct from the red-stained fibrous scar 
tissue and/or other structures. In contrast, in routine hematoxylin and eosin 
staining (Figure 1E; p.28), the amyloid material could be missed.
1.1.4. distribution and morphology of ttr-based amyloid in  
    the pulmonary tissue (tanskanen et al., unpublished data)
In this series of 256 individuals, pulmonary tissue samples were examined in 
164. Among these, only two subjects (1%) had detectable amyloid in blood 
vessels in the lung tissue but not in the heart.
1.2. Frequency of CAA (II, III)
1.2.1. Frequency of cAA in a population aged 95 years or  
    more (ii, iii)
In study II, Congo red positivity (Figure 2A,B; p.34) was detected in 
histological analyses of frontal, parietal, temporal, cingular, and cerebellar 
cortical specimens from 36 (36/74; 49%) of the 74 study subjects, in 
altogether 99 (99/370; 27%) of the tissue samples analyzed. On average, 
three brain regions were involved. The Congo red-positive blood vessels 
were also reactive in the anti-Aβ IHC (II: Figure 3b; III: Figure 1). In a 
smaller subset of individuals (III, n=63), CAA was detected in 28 (44%) of 
the 63 individuals, where the prevalence was 42% (22/53) in females and 
60% (6/10) in males.
1.2.2. distribution of cAA in different brain regions (ii) 
CAA was most prevalent in the frontal cortex (30/99) and least frequently 
observed in the cerebellum (8/99). The score assignment for CAA severity 
was 1 in 22 (61.1%), 2 in 11 (30.6%), and 3 in 3 individuals (8.3%). Severe 
CAA was observed in 24 of 99 specimens (24%), and was most often located 
frontally (9/24, 37.5%). Mild CAA was the most common form, observed in 
64% of the specimens (64/99). A frequency of occurrence was comparable in 
the frontal (16/64), temporal (16/64), and parietal lobes (15/64). Moderate 
and severe CAA was found in 11% and 25% of the specimens, respectively (II: 
Figure 1). The amyloidotic blood vessels were generally devoid of leukocytes. 
The presence of leukocytes in CAA is rare. In addition to the cases where 
small infarction were associated with CAA (Figure 2A-D; p.34), scattered 
CD45-positive cells (leukocytes) were detected in a few samples with severe 
CAA.
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2. ASSOCIATION BETWEEN SSA AND CAA (III)
The study investigating the association between SSA and CAA was performed 
on 63 of the subjects aged 95 years or older, including 53 females and 10 
males, for whom both heart and cerebral specimens were available. Nine 
individuals (14%; seven women, two men) had both SSA and CAA, in 
contrast to 21 (33%; 19 women, two men) who neither had SSA nor CAA. 
Thus, 67 % of the subjects (42/63) had SSA, CAA, or both. In the statistical 
analyses, SSA was not associated with CAA (p=0.43 for all, 0.41 for women). 
Of the nine individuals with both SSA and CAA, both were grade 1 in four 
individuals. In two subjects, SSA grade 1 co-occurred with CAA grade 2-3, 
and in another two subjects, CAA grade 1 co-occurred with SSA grade 2-3. 
In one individual, both SSA and CAA were scored as grade 2-3.
3. CLINICAL FEATURES AND AUTOPSY FINDINGS 
IN SSA, CAA, AND AGEL AMYLOIDOSIS  
(I, II, III)
3.1. Age (I, II)
3.1.1. Age and ssA (i)
Characteristics of the SSA study (I) population and the number of individuals 
with or without SSA are shown in Table 10. The proportion of individuals 
with SSA clearly increased with increasing age at the time of death of the 
subjects. SSA was detected in 17% (11/65) of the individuals who died at 
the age of 85-89.9 years old, 23% (29/127) of those who died at the age of 
90-94.9 years, 32% (18/56) of those who died at the ages of 95-99.9 years, 
and 63% (5/8) of those reaching at least 100 years of age. The results reveal 
that SSA is significantly associated with the age at death (OR 1.13; 95% CI 
1.05–1.22; p=0.002). 
3.1.2. Age and cAA (ii)
Characteristics of the CAA study (II) population is illustrated in Table 10. 
In statistical analyses using linear regression, age was not associated with 
CAA (p=0.974).
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Table 10. Demographic and health-related characteristics of individuals with (+) or  
without (-) senile systemic amyloidosis and cerebral amyloid angiopathy.
Study I SSA+ SSA- Study II CAA+ CAA-
N 256 63 193 74 36 38
Age, yr* 92.5 ± 3.8 93.8 ± 4.3 92.0 ± 3.5 96.6
p=0.002a
Men, % 16 22 15 18 22 11
BMI*,** 3.0± 0.7 2.85 ± 0.7 3.05 ± 0.7
DM, % 22 21 23 3 20
p=0.021b
Hypertension, % 29 31 28
Smoking***, % 16 21 14
Dementia, % 65 52 73 66 81 53
0.01
Heart weight, g* 356.6 ± 89.5 381.7 ± 106.6 348.8 ± 81.9 320.8±63.4 377±101.6
p=0.015a p=0.017b
MI, % 40 50 37 29 44
SSA = senile systemic amyloidosis; CAA = cerebral amyloid angiopathy; SD = standard deviation;  
BMI = body mass index = weight divided by height squared.
*Mean ± SD.
**BMI values were classified into five categories: 1 ≥ 32; 2 = 28-31; 3 = 19-27; 4 = 15-18; 5 ≤ 14 
***In 1991.
aWhen comparing the subjects with (+) or without (-) SSA.
bWhen comparing the subjects with (+) or without (-) CAA.
3.2. Gender (I, II)
3.2.1. Gender and ssA (i)
The proportion of males in the SSA study (I) was 17% (43/256) and 83% 
(213/256) for females. Of all subjects having SSA, 22% (14/63) were males 
compared to 15% (29/193) in the SSA population (Table 10). The overall 
frequency of SSA did not associate with gender. Severe (grade 3) SSA 
occurred in 10% (4/43) of the males compared to 1% (2/213) in females, 
indicating significant association between severity of SSA and the male 
gender (p=0.022).
3.2.2. Gender and cAA (ii)
The population in the CAA study (II) included 13 males and 61 females. Out 
of the 36 individuals having CAA, 22% (8/36) were males and 78% (28/36) 
females whereas 11% (4/38) were males in the controls (CAA subjects). 
Among all 36 subjects with CAA, it was severe in 25% (2/8) of the males 
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compared to only 3% (1/28) of the females. Statistically, gender was not 
associated with CAA (p=0.237).
3.3. Health-associated risk factors (I) 
3.3.1. Bmi (body mass index), diabetes mellitus (dm), 
    hypertension (Ht), smoking, and ssA (i)
The mean BMI (body mass index = weight divided by height squared; 
classified into five categories: 1 = ≥ 32; 2 = 28-31; 3 = 19-27; 4 = 15-18; 
5 ≤ 14) values for individuals with SSA (n=256, study I) were 2.85 ± 0.7, 
compared to 3.05 ± 0.7 for those without SSA (Table 10). Low BMI showed 
a non-significant tendency towards association with SSA (p=0.053). SSA 
was not associated with DM, HT, or smoking (Table 10).
3.3.2. Bmi, dm, Ht, smoking, and cAA (tanskanen et al., 
    unpublished data)
DM was detected in one individual (1/35; 3%) of those having CAA, in 
contrast to eight individuals (8/40; 20%) from those not having CAA (Table 
10). The proportion of non-diabetics was 97% (34/35) in the CAA-positive 
population and 80% (32/40) in the CAA-negative population. There was 
significant association between lack of DM and CAA (p=0.021). CAA was 
not associated with BMI, HT, or smoking (Table 10).
3.4. Clinical dementia (II, III)
3.4.1. dementia and ssA (iii)
The association between dementia and SSA was studied in the 63 subjects 
(study III, 53 women, 10 men) aged 95 years or more. In this population, 
36% of the subjects (23/63; 19 women, four men) had SSA. Clinical dementia 
was stated in 65% (41/63; 36 women, five men). Of the 23 SSA+ individuals, 
dementia was clinically diagnosed in 52% (12/23; ten women, two men). Out 
of the 12 demented SSA+ individuals, 67% (8/12) had clinical AD (six women, 
two men) and 33% (4/12, four women) had other types of dementia. There 
were 40 individuals without SSA, in whom clinical dementia was diagnosed 
in 73% (29/40; 26 women, three men). In the subjects without SSA, AD was 
diagnosed in 55% (16/29;15 women and one man) and other dementias in 
45% (13/29; 11 women and two men). In the statistical analyses, SSA was not 
associated with clinical dementia, AD, or other dementias. In both groups 
of individuals (SSA+ and SSA-), the same number of individuals (11) had 
normal cognition.
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3.4.2. dementia and cAA (ii, iii)
In study II, 66% (49/74) of the 74 study participants were demented. Out 
of the 36 individuals having CAA in this study, dementia was stated in 81% 
(29/36). Out of the 29 demented patients with CAA, AD was clinically 
diagnosed in 62% (18/29), vascular dementia in 24% (7/29), and other 
dementias in 14% (4/29). Of the 49 clinically demented individuals, 59% 
(29/49) had CAA with 26% (13/49) having moderate or severe CAA (grades 
2 or 3). CAA occurred in 28% (7/25) of the 25 non-demented individuals, 
but only one subject had grade 2 or 3. CAA was significantly associated with 
clinical dementia (p=0.01; II: Table 1c), particularly moderate or severe 
CAA (p=0.003; study II). However, dementia was not associated with the 
severity of CAA (p=0.22; II: Table 1d).
Study III examined a somewhat smaller subset of the most elderly 
population. In this study, the results for dementia and CAA were in line 
with study II, as dementia was stated in 79% (22/28) of the individuals 
having CAA and only 59% (19/37) of those not having CAA.
3.5. Clinical, laboratory, and radiological findings in AGel 
amyloidosis (IV)
At age 78, the patient had a facial appearance characteristic of AGel 
amyloidosis, dysarthria, facial myokymic diplegia, corneal areflexia, and 
atrophy of muscles of the face, neck, and shoulders. Minor muscle weakness 
and atrophy in the proximal lower and distal upper limbs, and sensory 
impairment in the limbs and trunk were stated. The tongue was atrophic 
with an enlarged base. Deep tendon reflexes were abolished, and plantar 
responses were flexor. The main clinical problem was a severe ataxia such that 
standing and sitting upright were difficult. All laboratory tests were normal 
apart from minor blood leukocytosis (10.4 E9/L) and a slight elevation of 
the α2-globulin fraction (9.3 g/L; normal 4.5-8.9 g/L). The G654A gelsolin 
gene mutation was diagnosed by solid-phase minisequencing (Paunio et 
al., 1992a). Radiologically, moderate brain and spinal cord atrophy with 
occasional unspecific foci in the cerebral white matter occurred. The images 
also reveal atrophy and fatty degeneration of the multifidus and longissimus 
dorsi muscles of the back and less pronounced atrophy of the hamstring 
muscles of the thigh. In the neurophysiological studies, the motor nerve 
conduction velocities were slightly abnormal with low amplitude responses. 
The sensory response in the sural nerve was absent and its amplitude in the 
radial nerve low. The F-response of the posterior tibial nerve was delayed. 
In the needle EMG, severe generalized chronic axonal neuropathy with loss 
of motor unit potentials (MUPs) occurred. Long duration, high amplitude 
polyphasic MUPs were seen in all limb and trunk muscles. In the facial 
muscles, total paralysis was found with only single MUPs detected in the 
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orbicularis oculi muscle. Severe MUP loss also occurred in the lingual, 
masseter and platysma muscles. At somatosensory evoked potential (SEP) 
examination, no peripheral- or thalamocortical responses were able to be 
elicited at median nerve stimulation. In quantitative sensory testing (QST), 
the sensations of vibration, as well as cold and warm temperature in upper 
and lower extremities were abnormal. Pain sensation for cold was normal, 
but heat pain sensation was abnormal in the hypothenar area.
3.6. General autopsy findings (I)
3.6.1. Heart weight and myocardial infarctions (mis) in ssA (i) 
In 50 % of the histological samples from individuals with SSA, acute MIs 
or older scars were detected compared to 37% in those without SSA (Table 
10). In the Chi-Squared or exact test for linear categorical variables, the MIs 
showed a nonsignificant tendency towards association with SSA (p=0.076). 
However, in the logistic regression analysis (I: Table IV), after controlling 
for confounding factors, a significant association between SSA and MIs was 
detected (p=0.004). 
The mean weight of the heart was 382 ± 107g in subjects with SSA, and 
349 ± 82g in those without SSA (n= 256; Table 10). The difference between 
the groups was statistically significant (OR=1.004; 95% CI 1.001–1.007; 
p=0.015). In addition, the weight of the heart was very strongly associated 
with MI (p=0.000).
3.6.2. Heart weight and mis in cAA (tanskanen et al., 
    unpublished data)
The mean weight of the heart in individuals with CAA was 320.8g (SD= 
63.37, SE= 11.57), and 377.4g (SD= 101,57, SE= 17,18) in those without 
CAA (Table 10). Increased heart weight associated significantly with the 
absence of CAA (p=0.017). Nine (29%) old scars or acute infarctions were 
detected in the cardiac samples of individuals having CAA, compared with 
16 (44%) in those without CAA. Statistically, the difference between these 
groups was not significant.
3.7. Neuropathological findings (II, III, IV)
3.7.1. cerebral infarctions and hemorrhages in cAA (ii)
The presence of cortical ischemic lesions or hemorrhages was studied in 
74 individuals aged 95 years or older (II). Twelve small cortical infarcts, 
scars, or small anoxic lesions were found in 11 samples (12/99; 12.1%) from 
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nine individuals with CAA (9/36; 25%). Anatomically, these small vascular 
lesions were located closely to the amyloidotic blood vessels (Figure 2A-D; 
p.34). Seven of these CAA+ individuals had clinical AD, one had vascular 
dementia, and one was not demented. A large acute infarction was stated 
in one individual without CAA (1/38; 3%).
In 13 individuals with CAA (13/36; 36%), iron-positive macrophages and 
erythrophages indicating earlier minor blood extravasation or hemorrhage 
(Figure 2F; p.34) occurred in 22 samples (22/99; 22%). In all samples, 
the amount of iron was minor. No major hemorrhages were found. In 17 
individuals without CAA (17/38; 45%), 22 iron-positive samples (22/190; 
12%) were detected. 
3.7.2. neuropathological Ad and cAA (ii, iii)
Senile plaques and neurofibrillary tangles represent the neuropathological 
hallmarks of AD. In the present study (II), the presence of CAA was compared 
to the presence of histopathological AD findings according to the NIA-RI 
criteria of AD pathology described earlier (Polvikoski et al., 2001). Out of the 
36 individuals having CAA, clinical dementia was stated in 29 (29/36; 81%). 
In histological samples from these 29 demented individuals, 22 subjects 
(22/29; 76%) fulfilled the histopathological criteria of NIA-RI AD. Out of 
the 38 subjects not having CAA, 20 were demented (20/38; 53%) and nine 
(9/20; 45%) had neuropathological AD. Statistically, CAA was significantly 
associated with NIA-RI AD (p=0.0005; II: Table 2a). Interestingly, a subset 
analysis of CAA+ subjects also showed that CAA was associated with clinical 
dementia in subjects without NIA-RI AD pathology (II: Table 2b), and thus 
the association between CAA and clinical dementia did not depend upon 
histopathological AD in this age group.
3.7.3. neuropathological Ad and ssA (iii)
In study III, only four individuals out of the 23 subjects with SSA had 
frequent plaques using the CERAD criteria for neuropathological AD (Figure 
3E), and four had neurofibrillar stage 5-6 in the Braak staging system for 
neuropathological AD (Figure 3F). The corresponding numbers in the 40 
subjects without SSA were three and nine, respectively (Figure 3 E,F). In the 
statistical analyses, SSA was not associated with neuropathological AD.
3.7.4. neuropathological findings in advanced AGel  
    amyloidosis (iV)
Neuropathological examination revealed marked gelsolin amyloid 
deposition at vascular and connective tissue sites along the entire length of 
the peripheral nerves extending to the spinal nerve roots, associated with 
severe degeneration of affected muscle tissue (IV: Figure 1d), nerve fibers 
and the posterior columns (IV: Figure 1e). In the case of advanced AGel 
amyloidosis, the loss of myelinated axons and reduced density of neuronal 
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Figure 3.
Number of individuals with or without SSA, and with or without CAA (A), clinical dementia (B), 
clinical AD (C), other dementia (D), frequent neuritic plaques according to CERAD criteria (E) and 
neocortical neurofibrillar tangles (F).
Abbreviations: dem = dementia; non-AD = other types of dementia than AD; C.F = frequent 
neuritic plaques corresponding to class C for individuals aged >75 years in CERAD classification; 
C.s,m = no, sparse or moderate plaques, corresponding to class 0, A, or B for individuals aged 
>75 years in CERAD classification; Br.5,6 = Braak stages 5 and 6, corresponding neocortical 
neurofibrillar stage; Br.0.4 = Braak stages 0-4, corresponding to no, entorhinal or limbic 
neurofibrillar stages. 
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cell bodies in the hypoglossal nerve nucleus was clearly detectable by using 
SMI311, a pan-neurophilament protein antibody cocktail. Myosin Heavy 
Chain fast antibody, which stains the type 2 fibers of skeletal muscle while 
leaving the type 1 fibers unstained, was used to specify the type of muscle 
atrophy in the patient with advanced AGel amyloidosis. In this patient, both 
the stained type 2 fibers as well as the unstained type 1 fibers were atrophic, 
indicating a combination of inactivity and denervation atrophy (IV: Figure 
1d). In the brain, some cerebral blood vessels showed amyloid that reacted in 
anti-variant gelsolin IHC. Numerous diffuse, but only a few neuritic plaques 
and neurofibrillary tangles, were seen in the cerebral cortex.
4. GENETIC POLYMORHISMS IN SSA AND  
CAA (I, II)
4.1. Genetic polymorphisms in SSA (I)
The results of the genetic association studies in SSA and CAA are shown 
in Table 11. SSA associated significantly with the single nucleotide 
polymorphism (SNP) G/G genotype in exon 24 of the α2M gene (p=0.042). 
This polymorphism also showed significant association with the severity 
of SSA (p=0.012). Further, the exon 9 deletion/insertion (H1/H2) 
polymorphism of the tau gene was significantly associated to SSA (p=0.016), 
as well as the severity of SSA (p=0.003). In order to find out if the TTR 
gene itself was associated with SSA, the coding regions of the TTR gene 
were sequenced in six individuals with grade 3 SSA. This analysis showed 
the predicted wildtype sequence in five cases, but one individual had the 
A/G genotype in exon 2 of the TTR gene. This SNP, denoted rs1800458, 
can be found in the NCBI database (http://ncbi.nlm.nih.gov/entrez/query.
fcgi?CMD=search&DB=snp) and is predicted to result in a non-synonymous 
amino acid change (Gly26Ser). This SNP was subsequently analyzed in 
all 256 study. Two homozygous (Ser/Ser) and 47 heterozygous (Gly/Ser) 
individuals were found, while 188 subjects were homozygous for the wildtype 
allele (PCR failed in 19 samples). The allele frequency was 0.11, and there 
was no significant difference between the allelic frequencies in individuals 
with, or without, SSA.
SSA was not associated with the exon 18 polymorphism of the α2M gene, 
the tau RS3758, RS24717, and RS7521 polymorphisms, APOE genotype, nor 
the ACE, LPL, LRP, or Prion protein polymorphisms.
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Table 11. The results of association analyses comparing the genotype distributions 
of subjects with or without senile systemic amyloidosis (SSA) and cerebral amyloid 
angiopathy (CAA).-
Gene/ polymorphism p-value/SSAa p-value/CAAb
Angiotensin converting enzyme
Insertion-deletion n.s. n.s.
Alpha2-macroglobulin
Exon 24 (Ile1000Val) 0.042* n.s.
Intron17/Exon 18 (5 bp del) n.s. n.s.
Apolipoprotein E 
ε2/3/4 n.s. 0.01**
Promoter -219 n.s. n.s.
Promoter -491 n.s. n.s.
Intron IE1 n.s. n.s.
Beta-amyloid cleaving enzyme2
Intron 1a n.s. n.s.
Intron 1b n.s. n.s.
Exon 6 n.s. n.s.
Exon 8 n.s. n.s.
Lipoprotein lipase
Ser447Ter n.s. n.s.
Asn291Ser n.s. n.s.
Low-density lipoprotein receptor -related protein
Exon 6 n.s. n.s.
Prion protein gene 
C129 M/V n.s. n.s.
Tau
H1/H2 0.016*** n.s.
RS3785883 n.s. n.s.
RS2471738 n.s. n.s.
RS7521 n.s. n.s.
Transthyretin
RS18004 n.s. n.s.
SSA = senile systemic amyloidoisis; CAA = cerebral amyloid angiopathy; n.s. = not significant.
aWhen comparing subjects with and without SSA.
bWhen comparing subjects with and without CAA.
*Chi-squared test for linear trend.
**Chi-squared test.
***Exact test for linear trend.
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4.2. Genetic polymorphisms in CAA (Tanskanen M et al., 
unpublished data)
One copy of APOE ε4 was found in 15 (45%) subjects with CAA compared 
with three (8%) individuals without CAA (χ2=13.17, 1 df, p=0.0003). 
No association with ε2 was found. In addition, moderate to severe CAA 
was associated with APOE ε4 (p=0.03) but not mild CAA. CAA was not 
associated with polymorphisms in the following genes: α2M, tau, TTR, ACE, 
LPL, LRPR, or Prion protein (Table 11).
5. IHC FOR AMYLOID-ASSOCIATED AND OTHER 
PROTEINS (I, II, IV)
5.1. Amyloid proteins and Congo red (I, II, IV)
All Congo red-positive structures in the myocardium (I) reacted in the anti-
TTR IHC. Similarly, all Congo red-positive cerebral cortical blood vessels 
(II) reacted in the anti-Aβ IHC, and the amyloid deposits in the patient with 
AGel amyloidosis (IV) reacted with anti-variant gelsolin IHC. In all types 
of amyloid, the immunohistochemical reaction was slightly broader than 
the Congo red positivity. 
5.2. AMed amyloid and CAA (Tanskanen et al., 
unpublished data)
In the medin study, Congo red staining detected CAA in nine out of the ten 
(90%) individuals with clinical AD. In one subject, there was no CAA in 
spite of moderate amounts of plaques. Among the nine individuals having 
CAA, it was mild in five, moderate in two, and severe in two subjects. In all 
subjects, vascular amyloid deposits reacted in Aβ IHC. The number of senile 
plaques in Aβ IHC ranged from sparse to frequent. In the seven clinically 
non-demented (control) individuals, there was no CAA and the Aβ IHC 
showed sparse senile diffuse, non-amyloid plaques in three subjects. In all 
cases, varying positivity in the anti-medin IHC was observed in the small 
and middle-sized arteries in the cerebral cortex and leptomeninges. However, 
positive reactivity was located outside the amyloid deposits. The finding 
became clearly evident when double staining with Congo red and medin was 
performed in cases of severe CAA with total damage of the arterial media. 
In the amyloidotic vessels, no reaction in the anti-medin ICH was noted. 
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5.3. Complement (C) proteins in CAA and AGel 
amyloidosis (II, IV) 
5.3.1. c3d and c9 in cAA (ii)
In CAA, most amyloidotic blood vessels showed reactivity for antibodies 
against C3d and C9 (II: Figure 1c,d). Reactivity in the anti-C3d IHC was 
detected in 89% (88/99) of the samples, and 84% (83/99) of the samples 
in the anti-C9 IHC. In all C3d/C9-negative samples, CAA was very mild 
(grade 1) with only 1-2% of blood vessels staining positive for Congo red or 
Aβ. Most complement-negative samples were negative in both complement 
stainings. The 11 samples with CAA and small cortical infarct(s) showed a 
less pronounced reaction for C3d and C9 than samples with similar CAA 
but without infarcts. No difference in IHC reactivity between C3d and 
C9 was seen when comparing CAA cases with or without iron. The IHC 
reactivity for C3d and C9 were highly congruent in the examined samples 
and co-localized with the congophilic, birefringent and Aβ-positive amyloid 
deposits (II: Figure 1c,d and Figure 2a,b).
5.3.2. c3d and c9 in AGel amyloidosis (iV)
The histological samples from the patient with advanced AGel amyloidosis 
showed positive reactions in the anti-C3d and anti-C9 IHCs. The reaction 
co-localized with Congo red and the anti-variant gelsolin IHC in the neural 
(IV:Figure 1h,j) and vascular structures.
5.4. Alpha2-macroglobulin (α2M) in the myocardium 
(Tanskanen et al., unpublished data)
Immunohistochemical staining using an antibody against α2M was 
performed on paraffin-embedded myocardial samples from 14 individuals 
with grade 2-3 SSA. The anti-α2M IHC was negative within myocardial 
amyloid deposits, but in contrast, the fibrous scar tissue in these samples was 
stained (Figure 1F). In addition, a positive reaction was seen in leukocytes 
present in the blood vessels.
5.5. Tau and phosphorylated tau in the myocardium 
(Tanskanen et al., unpublished data)
The anti-tau and anti-phosphorylated tau IHC was negative in the myocardial 
tissue samples.
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6. EFFECTS OF CLINICAL, PATHOLOGICAL, AND 
GENETIC FACTORS ON SSA AND CAA (I, II, III)
6.1. Multivariate analysis of the effect of MIs, age, and 
genetic variants of α2M and tau on SSA (I)
The association between SSA and α2M and tau was studied using logistic 
regression analysis to control for the possible confounding effects of age and 
MIs. The p-values for α2M and tau remained significant when age at the 
time of death and MIs were included in the analysis, implicating that the 
effects of tau and α2M genotypes were independent of the other variables 
(I: Table 4).
6.2. Association between dementia, CAA, APOE 
genotype, and histopathological AD (II)
CAA associated significantly with APOE genotype (p=0.0004), largely due to 
the increased frequency of ε3/4 and decreased frequency of the ε3/3 genotype 
in CAA. CAA also associated with dementia (p=0.01). However, dementia 
was not associated with APOE ε4 in this sample of individuals (p=0.23). 
Interestingly, the association between dementia and CAA was contributed to 
by both the ε4+ (p=0.01) and ε4- subjects (p=0.06). We tested whether CAA 
represents AD pathology in this group of individuals. Indeed, there was also 
a significant association between CAA and histopathologically-defined AD 
according to the NIA-RI criteria (p=0.0005). However, the subset analysis 
of CAA+ subjects suggests that CAA also associates with clinical dementia 
in subjects without NIA-RI-AD pathology. In conclusion, the association 
between dementia and CAA depends on neither APOE nor histopathological 
AD in this very elderly Finnish population.
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6.3. Association between dementia, SSA, and CAA (III)
Dementia was more common in individuals without SSA (73%) than in those 
with SSA (52%). CAA was common in demented individuals (54%), both in 
those with (58%) or without SSA (52%). In contrast, CAA was more seldom 
in individuals with normal cognition (28%), and this was independent of 
having SSA (18%) or not (36%) (Figure 4).
Figure 4.
The number of demented (grey columns) and non-demented (yellow columns) individuals in 
SSA+ and SSA- groups. In both groups, CAA (red numbers) is common in the demented, but 
uncommon in individuals who are not demented .
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DISCUSSION:
1. FREQUENCY AND DISTRIBUTION OF SSA  
AND CAA
In previous hospital-based series, SSA has been encountered in 25-28 % of 
autopsied subjects aged 80 years or over (Cornwell et al., 1983; Westermark 
et al., 2003). In the present population-based study (I), the prevalence of 
SSA was 25%, confirming SSA is common in an elderly population. In 
the present study, the standard myocardial sample was taken from the 
septum of the heart, a commonly used biopsy site for general autopsy. In 
other studies, the samples were taken from the “left ventricle” (Johansson 
and Westermark, 1991) or as “one large transverse section of ventricles” 
(Sawabe et al., 2003). Here, except for two individuals, SSA was detectable 
in all myocardial specimens taken. Based on this, one histological sample 
seems to be sufficient for the diagnosis of SSA. Apart from lack of awareness 
of SSA, other reasons for SSA being a rare histopathological diagnosis in 
general autopsy reports may include the presumably benign nature of SSA 
as well as the common use of hematoxylin-eosin (HE) staining in which the 
differentiation between amyloid material and fibrous tissue is more difficult. 
In addition to Congo red, amyloid can be detected and distinguished from 
fibrous scar tissue by using connective tissue stains. In every case, IHC is 
necessary in order to type the amyloid. In contrast, HE staining may be 
more informative in visualizing nuclear morphology, which can be helpful 
in diagnosing several common conditions potentially leading to death, e.g. 
malignant neoplasms. 
Here, the previous findings showing patchy distribution of SSA in different 
regions of the heart and the distribution in the individual myocardial samples 
(Cornwell et al., 1983; Westermark et al., 2003) was confirmed. Thus, the type 
of distribution of the SSA resembles the patchy distribution of CAA, reported 
previously (Ellis et al., 1996; Yamada, 2000) and even in the present study 
(II). SSA is a systemic disorder, and the haphazard distribution of amyloid in 
the tissue may be due to the the blood borne origin of the amyloid precursor 
protein, TTR. In addition, the predilection sites of amyloid deposition in SSA 
(heart and lung) might be due to the abundant vascularity that is typical to 
these organs. The myocardial amyloid deposits were not associated with scars, 
infarctions, anatomical regions, or even blood vessels in the tissue sections. 
However, the present finding is not conclusive, as the conventional stains 
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may not reliably detect the smallest blood vessels. IHC for endothelial cells 
(CD131, CD134), preferentially combined with serial sections perpendicular 
to the blood vessels, would be more informative. 
From several patients, there were pulmonary samples available that could 
be stained with Congo red. Interestingly, only 1 % of the subjects tested 
positively in the lungs but not in the heart. Thus, determining the occurrence 
of SSA by solely examining cardiac samples seems to be a reliable method.
CAA (II) was encountered in nearly half of the most elderly population, 
similar to a previous population-based study (Masuda et al., 1988). In other 
studies, the frequency of CAA has been shown to increase with increasing 
age of death of the subjects (Yamada et al., 1988; Masuda et al., 1988; Xu et 
al., 2003). The occurrence of CAA was not associated with age. However, the 
finding may not be conclusive as the number of patients in the CAA study 
was small, the patients represented a very specific age group, and finally 
because of their narrow age. The study (II) also clearly showed the patchy 
spatial distribution of CAA, ranging from one to five brain regions. The 
preferred site was the frontal cortex, as noted earlier (Masuda et al., 1988; 
Ellis et al., 1996; Yamada, 2000). In other reports, the occipital and parietal 
lobes have also been prevalent (Vinters and Gilbert, 1983), but unfortunately 
as in the study by Ellis et al. (Ellis et al., 1996), parietal lobe samples were 
not available here.
In this work, the methods used by Ellis et al. (Ellis et al 1996; Table 5, 
p.33; 8b, p.52) were chosen to assess the severity of CAA, for several reasons. 
By using these methods, several cortical regions can be studied, and clear 
guidelines are given on how to create an individual CAA score. Both of 
these aspects are essential in order to correlate CAA with clinical dementia. 
Secondly, comparing the severity of CAA with the amount of complement 
proteins necessitates that these two parameters are graded using the same 
system. Furthermore, the simple four-step semi-quantitative grading system 
used by Ellis et al. (grades 0 to3) is easy to apply to immunohistochemical 
complement stainings. The other methods (Table 5; p.33) were in some 
respects inadequate for this work: the method described by Vonsattel 
(Vonsattel et al., 1991) does not offer individual CAA scoring, and Olichney 
(Olichney et al., 1995) uses a complex five-step grading system. Thal (Thal 
et al., 2002), although precisely describing the findings in different blood 
vessel types, uses a simplified three-step grading system with minor attention 
to the extent that cerebral regions are affected.
Finally, the present study (III) shows for the first time the high frequency 
of SSA and CAA together, as either one or both of these conditions were 
present in almost two-thirds (see Results, Chapter 2) of the very elderly 
Finnish population. This finding highlights the potential clinical significance 
of these diseases, as at least CAA has remarkable clinical implications and/
or consequences (see Results, Chapter 3.4.2.).
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2. ASSOCIATION BETWEEN SSA AND CAA
In a population-based series, the present study (III) statistically proved for 
the first time that SSA and CAA are not associated with each other. This result 
has two implications in the amyloid field. Firstly, it opposes the theory on a 
common predisposing factor to amyloid formation. Secondly, as described 
in the previous chapter, the common occurrence of these conditions leads 
to the very common occurrence of one or both of them in the very elderly 
population. Only a few earlier reports have remotely touched upon the 
co-occurrence of SSA and CAA, and mostly in animals, not in population-
based series. In the report by Yamada (Yamada et al., 1988), the incidence 
of CAA and SSA are reported separately and without taking notice to the 
co-occurrence of the conditions. In addition, SSA was detected in only 3% 
of the participants. In the paper by Uchida (Uchida et al., 1991), CAA was 
observed in 28 out of 90 elderly dogs, noting that in “some of those having 
CAA, amyloid deposition was sometimes found in the vascular walls of the 
heart”. Uno (Uno et al., 1996) found CAA in 12 out of 81 monkeys, two of 
which had amyloid in the pancreas or liver. Unfortunately, cardiac amyloid 
was not mentioned.
3. CLINICAL, PATHOLOGICAL, AND GENETIC 
FACTORS IN SSA, CAA, AND AGEL 
AMYLOIDOSIS
3.1. Age, SSA, and CAA 
Although SSA and CAA were not associated (III) with one another, age 
represents a common denominator between these two conditions. In study 
I, the prevalence of SSA was not associated with age at death although the 
frequency of SSA clearly increased along with increasing age at the time of 
death of the subjects. Unfortunately, in that study, the prevalence numbers 
concerning different age groups do not represent the true prevalence for SSA, 
because the individuals who die at a certain age do not represent the whole 
population at that age. Concerning age and CAA, an association between 
these two parameters was not studied, as the population in the CAA study 
was small and the subjects were 95 years of age or more.
An interesting finding was the detection of association between the severity 
of SSA and age at the time of death. Adding this to the high frequency of both 
SSA and CAA, the finding raises the question whether amyloid formation 
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could represent an event associated with normal aging. Some evidence 
that may support this view include: the detection of amyloid plaques in the 
brains of non-demented subjects, CAA in leptomeningeal blood vessels in 
half of normal elderly individuals (Wu et al., 1992), and AMed amyloidosis 
in all subjects aged 60 years or more.. In addition, concerning TTR, certain 
biophysical conditions that destabilize the tetramer such as lowered pH have 
been noticed to accentuate the polymerization of certain mutants, but may 
even transform wildtype TTR protein into amyloid fibrils under laboratory 
conditions (McCutchen et al., 1993; McCutchen et al., 1995). Analogously, 
in living organisms, hypoxic conditions following decreased blood flow due 
to coronary atherosclerosis or cardiac insufficiency (common conditions in 
aged individuals), may lower environmental pH in the heart, thus favoring 
TTR-based amyloid formation. In addition, some of the hereditary amyloid 
disorders manifest clinically at middle or even old age, although the genetic 
defect has been present since birth, indicating an association of the clinical 
disease with accumulation of amyloid during time. This is clearly seen in 
TTR-related FAP, where orthotopic liver transplantation, by eliminating the 
source of the amyloidogenic TTR molecule, stops the progression of the 
disease (Herlenius et al., 2004). CAA is also suggested to be a consequence 
of decreased Aβ elimination from brain tissue (Feurer and Weller, 1991; 
McLean et al., 1999) that becomes evident only with the progression of 
time.
3.2. Gender, SSA, and CAA
The severity of SSA (I) associated with male gender, although the overall 
frequency of SSA did not significantly differ between genders. In previous 
studies, SSA has been observed more often in men than in women (Johansson 
and Westermark, 1991; Kyle et al., 1996; Ng et al., 2005). Presumably, these 
hospital-based studies have suffered from selection bias, because more severe 
myocardial amyloidosis in men is more likely to be detected than mild 
disease in women. On the other hand, the relatively small number of men 
in the present study (I) may also have affected the results. 
As in SSA, the overall frequency of CAA was not associated with gender 
either. This is in line with the previous population-based study (Masuda et al., 
1988) in which the frequency of CAA was relatively equal in men and women 
aged 90 years or over (42.8 % and 45.8 %, respectively). In the present study, 
the severity of CAA associated significantly with male gender, similiarly 
to severity of SSA. In the previous study by Masuda et al., the association 
between gender and severity of CAA was not mentioned in particular.
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3.3. Health-associated risk factors, SSA, and CAA
No previous studies on risk factors for SSA have been available. Although 
no significant associations were found in study (I), a trend was seen between 
low BMI and SSA. This trend may be relevant, since diabetes which is not 
associated with SSA, is associated with obesity or high BMI. However, there 
are difficulties in interpreting the results with BMI because of its lack of 
discriminatory power to differentiate body fat and lean mass (Romero-
Corral et al., 2006).
In line with a previous study (Yamada et al., 1987), CAA was not associated 
with HT, smoking, or BMI. However, there was a negative association between 
DM and CAA, with DM seemingly protecting against CAA. The finding is 
somewhat unexpected as DM, especially type II DM, has been noted to be 
a risk factor for dementia (Sima and Li, 2006) which is, in part, strongly 
associated with CAA (see Results, Chapter 6.2.). The explanation is most 
probably due to the overall small number of participants in the CAA study, 
and especially to the small number of diabetics in this age cohort, presumably 
due to the decreased life expectancy of diabetics (Franco et al., 2007).
3.4. Dementia, SSA, and CAA
No previous reports have been available on the occurrence of dementia in 
patients with SSA. The present study (III) revealed that clinical dementia 
is not associated with SSA. In both SSA+ and SSA- groups (see Results, 
Chapter 3.4.1.), the same number of individuals (11) had normal cognition 
although the number of individuals in the SSA- group was clearly larger, 
which raised the question of whether there may be an association between 
SSA and preserved cognition. However, this tendency was not statistically 
significant (p=0.09 for all, 0.07 for women). 
The present study (II) revealed a significant association between clinical 
dementia and CAA, consistent with previous studies (Neuropathology 
Group. Medical Research Council Cognitive Function and Aging Study, 
2001; Pfeifer et al., 2002). In the present very elderly Finnish population, 
clinical dementia was strongly associated with CAA, and this association 
was even independent of APOE. The APOE ε4 allele also represents a risk 
factor for neuropil-associated Aβ deposition, including cortical capillary Aβ 
(Thal et al., 2002). As the APOE ε4 allele is strongly associated with clinical 
dementia, a tempting question was raised of whether capillary CAA in 
particular was associated with dementia in this population as well. However, 
this question remains unanswered here, for several reasons mentioned 
previously (pp. 74-75) since the presence and severity of CAA was studied 
using the method by Ellis (Ellis et al., 1996, Table 8b, p.52) that does not 
divide CAA into capillary and non-capillary forms.
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Here, the association between clinical dementia and CAA was 
independent of neuropathological AD. In study II, the modified criteria 
for neuropathological AD were used. The basis for this was that if the 
original grading system would have been applied, there would have been 
a proportion of individuals who could not have been categorized at all, 
because there is no true linkage between the density of neuritic plaques and 
the Braak staging system (Geddes et al 1997, Knopman et al., 2003). As a 
consequence, the number of individuals who potentially could have been 
included in the study, would have been even smaller. On the other hand, the 
modified system may have yielded a greater proportion of individuals with 
neuropathological AD compared to if the original criteria had been used. 
However, the association between CAA and neuropathological AD in study 
II was so strong (p=0.0005) that it is very unlikely that using the original 
criteria would have changed the result to non-significance. In study III, the 
neuropathological findings were classified using the original CERAD and 
Braak classifications.
Dementia is the leading cause for the institutional care of elderly 
individuals in Western countries (Macdonald and Cooper, 2007) including 
Finland (Nihtila et al., 2007), and it creates a substantial economical burden 
to the society, e.g. more than 60 billion dollars annually in the USA (Gorshow, 
2007). Because of this, CAA is worth more attention, especially as it may 
present a potential target for medical therapy for clinical dementia. The 
interrelationships between dementia, CAA, and APOE are discussed in 
detail in the Discussion Chapter 6.2.
3.5. Clinical, laboratory, and radiological findings in  
AGel amyloidosis
Typical to AGel amyloidosis, the patient in study IV was not demented. 
He had severe PNP with prominent position and vibration sense losses, 
areflexia, pseudoathetosis, and ataxia. AGel amyloidosis patients may have 
mild peripheral neuropathy (Kiuru, 1998), but loss of stance and gait has 
been rare (Conceicao et al., 2003; Klaus et al., 1959; Kiuru, 1992). Severe 
ataxia has been previously reported only in one Portuguese patient who did 
not show any clinical or electrophysiological signs of peripheral neuropathy 
(Conceicao et al., 2003). Mild ataxia has been shown in Dutch, North 
American, and Finnish patients (Darras et al., 1986; Kiuru et al., 1999; 
Kiuru, 1992; Winkelmann et al., 1985), and severe non-cerebellar ataxia 
in a Czech patient (Klaus et al., 1959) suggests that severe ataxia can also 
represent a manifestation of G654T-related (de la Chapelle et al., 1992) AGel 
amyloidosis. The present study (IV) clearly showed that advanced AGel 
amyloidosis clinically manifests with severe ataxia.
MRI studies in the patient revealed atrophy of the spinal cord, which 
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can indicate involvement of the posterior columns. In the brain, minor 
abnormalities related to age rather than to cerebral AGel angiopathy 
were seen (Kiuru et al., 1999). The advantage of skeletal muscle MRI in 
amyloid diagnostics has previously been demonstrated in AL amyloidosis 
(Comesana et al., 1995; Hull et al., 2001; Metzler et al., 1992). In this patient, 
skeletal proximal leg and back muscle atrophy and fatty degeneration were 
shown indicating that MRI studies are helpful in amyloid diagnostics. The 
electrophysiological findings of− decreased or absent sensory potentials and 
absent SEP responses resemble the ataxic neuropathies (Dalakas and Quarles, 
1996). Aberrant central sensory conduction, described in AGel amyloidosis 
previously (Conceicao et al., 2003; Kiuru and Seppalainen, 1994), may reflect 
degeneration of central sensory projections, a common phenomenon in 
sensory ataxia (Lauria et al., 2000). In addition, the electrophysiological 
studies were consistent with severe chronic sensorimotor neuropathy, mainly 
with axonal nerve involvement, confirming previous electrophysiological 
(Kiuru et al., 1999) and sural nerve morphometric studies (Kiuru-Enari et al., 
2002). QST may be helpful in differentiating AGel neuropathy from variant 
TTR-, APOA1-, and AL-amyloid-associated neuropathies with preferential 
pain and sensory sense losses (Koike et al., 2004).
3.6. General autopsy findings in SSA and CAA
The Chi-squared test showed a trend for association between MIs and SSA, 
analogous with a previous hospital-based study (Cornwell et al., 1983). The 
present study confirmed this finding by showing significant association 
between these parameters in logistic regression analysis after standardizing 
for confounding factors, which may be inversely associated with SSA. 
Increased heart weight at the autopsy, a common observation in various 
myocardial diseases, was also associated with SSA. Here, even heart weight 
and MIs associated with each other very strongly, with a p-value of 0.000. 
Although it is not possible to prove causality by using statistical methods, a 
possible explanation may be that the MIs result in increasing heart weight in 
the acute phase of infarction due to tissue reactions following hypoxic injury, 
and also later in the form of scar tissue and reactive hypertrophy of the heart 
muscle cells. The close association between MIs and SSA leads to a tempting 
hypothesis that, analogous with CAA, SSA could cause small infarctions due 
to obliteration of the lumen of the peripheral vessels. However, in order to 
prove this, it would be advisable to examine larger specimens, including 
coronary arteries or their branches as well as the smallest peripheral vessels, 
combined with IHC to visualize the blood vessels.
The association between increased heart weight and lack of CAA (see 
Results, Chapter 3.6.2.) is in line with the lack of association between SSA 
and CAA (III).
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3.7. Neuropathology in SSA, CAA, and AGel amyloidosis
3.7.1. Brain pathology in ssA, cAA, and AGel amyloidosis
Although TTR-related amyloid has previously been detected in almost 
every organ of the human body, it was not found in the brain (Pitkänen et 
al 1984). Thus, SSA was not expected to be associated with, or cause, any 
brain events. Indeed, no statistical association was noted between SSA and 
CAA, neuropathological AD, or clinical dementia (III).
Small infarctions and large lobar hemorrhages have been regarded as typical 
findings associated with CAA (Mandybur, 1986; Vinters, 1987; Olichney 
et al., 2000). In the present study (II), small infarctions were frequently 
encountered, representing an essential feature of CAA in this sample of 
very old individuals. Small cerebral cortical infarctions may be assumed to 
be caused by amyloid deposition in the arterial wall, followed by thickening 
and subsequent obliteration of the lumen. Large lobar infarctions, however, 
were not encountered in the present study (II) in CAA patients. The exact 
mechanism of hemorrhage in CAA is not known. One explanation, proposed 
by Maeda et al. after performing a computer-assisted three-dimensional image 
analysis, was that vascular amyloid deposition causes degeneration and loss 
of smooth muscle cells of media, followed by microaneurysmal dilatation, 
fibrinoid necrosis, and rupture of the vessel walls (Maeda et al., 1993). This 
view was supported by the findings of Winkler et al. in their mouse model 
of Aβ-related CAA, in which amyloid deposition was accompanied by an 
extensive loss of medial smooth muscle cells (Winkler et al., 2001). The 
analysis of living canine leptomeninges has also shown that Aβ amyloid 
deposition is associated with loss of vessel wall viability (Prior et al., 1996). 
Furthermore, small deposits of amyloid fibrils or protofibrils have been 
reported to exert toxic effects on cells in their vicinity and induce cell death 
(Lorenzo et al., 1994; Schubert et al., 1995; Janson et al., 1999). Thus, the 
present study (II) indicates that lobar hemorrhages associated with CAA 
preferentially occur before age 95, or even 85, as noted even previously. 
Because such hemorrhages often are lethal, they do not represent a major 
medical problem in the very elderly. The present study (II) also showed a 
significant association between CAA and neuropathological AD, in line 
with a previous study (Pfeifer et al., 2002). AD has been proposed to be 
a consequence of hypoperfusion of the brain (de la Torre, 1994). Thus, in 
addition to senile plaques and neurofibrillar tangles, which have traditionally 
been considered as neuropathological hallmarks of AD, it can be speculated 
that CAA may also, at least partly, share the same origin. In addition, it 
possible that the perfusion of the brain is somehow related with drainage and 
the drainage theory of CAA origin by Weller et al (Weller et al., 1998). 
The cerebral findings in the patient with advanced AGel amyloidosis 
were such as could be expected due to his clinical status: minor amount of 
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variant Gelsolin-based amyloid in the cerebral blood vessels, noted even 
previously (Kiuru et al., 1999), and sparse diffuse (non-amyloid) plaques 
in the cerebral cortex, consistent with normal aging.
3.7.2. Pathology of the spinal cord and peripheral nerves in 
    AGel Amyloidosis and ssA 
The clinical findings in the patient with advanced AGel amyloidosis indicated 
sensory ataxia. Neuropathological studies showed amyloid deposition and 
atrophy in several levels of the proprioceptive pathway, consistent with earlier 
pathological reports (Kiuru et al., 1999; Kiuru-Enari et al., 2002). SMI311, an 
antibody cocktail which stains myelinated nerve fibers, proved to be helpful 
in showing atrophy in histological samples of the nervous structures. Apart 
from revealing severe degeneration in the posterior columns of the spinal 
cord, noted even earlier (Kiuru et al., 1999), this staining showed for the 
first time the substantial degeneration in the nucleus of the XIIth cranial 
nerve. This finding in part explains the typical manifestation of the disease: 
swallowing difficulty. Another cause for this symptom may be enlargement 
of the tongue, secondary to muscle atrophy and amyloid accumulation. The 
main differential diagnostically relevant disorders for posterior column, 
sensory root and/or nerve involvement include tabes dorsalis and diabetic 
pseudotabes, which were excluded in this patient. Here, severe ataxia led 
the patient to bed rest and finally resulted in peripheral venous thrombosis, 
pulmonary embolism, and death. In addition to describing severe ataxia 
in association with AGel amyloidosis, this case report (IV) also shows that 
AGel amyloidosis can be fatal.
In SSA, TTR-based amyloid is largely distributed within the organs but 
no published reports exist on PNP and/or ataxia in the disease (Cornwell et 
al., 1995). However, the question whether wildtype TTR can cause PNP is 
clinically relevant regarding several forms of hereditary TTR amyloidosis, 
especially the most common hereditary TTR amyloidosis in Scandinavia, 
which is caused by the Val30Met mutation and is the PNP form that causes 
major disturbance to the patients. Unfortunately, histological samples from 
spinal cord, spinal nerve roots, or peripheral nerves were not included in 
the present study setting and thus were not available for neuropathological 
investigation.
Aβ is normally expressed in the dorsal columns and in the peripheral 
nerves in both individuals with and without AD (Arai et al., 1991). In the most 
frequent of the age-associated muscle diseases, inclusion body myositis, Aβ is 
a typical constituent (Askanas et al., 1992). The background of instabililty of 
gait, a quite common finding in AD patients, is due rather to anoxic lesions 
and small infarctions in the brain tissue that are caused by CAA.
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3.9. Neuroinflammation
In the present study (II), special interest was focused on inflammation in 
CAA, and study IV also included an investigation of complement proteins 
in AGel amyloidosis. The finding of only a few leukocytes around the 
amyloidotic blood vessels in CAA is in line with earlier reports (Yamada et 
al., 1996; Eng et al., 2004). During the last 15 years, numerous inflammatory 
mediators have been observed in AD brains (Akiyama et al., 2000), suggesting 
that AD may be considered a representative of an inflammatory disorder. 
Interestingly, the chronic inflammatory response in AD is thought to be 
locally induced by Aβ without any apparent influx of leukocytes from 
the circulation (Eikelenboom et al., 2000; Rogers et al., 1992). Indeed, no 
substantial amount of leukocytes was observed histologically, neither around 
the cerebral cortical senile plaques nor in any of the other amyloids studied 
here (SSA and AGel amyloidosis). Complement proteins were present in 
both amyloid types in which they were studied. Thus, it may be suggested 
that in amyloid deposits, other factors than leukocytes from the circulation 
may be able to activate complement. The particular role of complement in 
CAA and AGel amyloids is discussed later (see Discussion, Chapter 5). 
4. GENETIC POLYMORPHISMS, SSA, AND CAA
4.1. TTR gene polymorphisms
Apart from the gene for TTR, there are no previous population-based reports 
on potential genetic risk factors in SSA. In the only published genetic study 
on SSA (Gustavsson et al., 1995), the coding sequence for TTR in two patients 
was sequenced without finding any mutations. This study was extended 
by performing a similar analysis on six individuals with severe (grade 3) 
SSA. Five of the individuals studied had the predicted wildtype sequence, 
but one carried a nonsynonymous rs1800458 SNP polymorphism on exon 
2 of the TTR gene. This SNP leads to the replacement of glycine to serine 
in TTR (Gly26Ser mutation), which is a common non-amyloidogenic 
polymorphism in Caucasian populations (Jacobson et al., 1995). In the whole 
study population (study I; n=256), the allele frequency was 0.11, which is 
even somewhat more than reported previously. There was no difference in 
the allele frequencies among subjects with or without SSA. Thus, the finding 
indicates that genetic variation in the TTR gene is an unlikely explanation 
for the development of SSA.
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4.2. α2M polymorphisms
The candidate gene screen in the present study (I) showed a significant 
association between SSA and exon 24 polymorphism in the α2M gene 
in our study population. α2M is a pan proteinase inhibitor found in the 
senile plaques of AD (Rebeck et al., 1995), in the tissue deposits of AA 
(inflammation-associated, formerly referred to as secondary amyloidosis) 
(Muller et al., 2000), and in the affected tissues in β2-microglobulin (dialysis)-
associated amyloidosis (Campistol et al., 1992). The gene for α2M is located 
on chromosome 12. A genetic association between AD and a polymorphic 
site upstream from exon 18 (Blacker et al., 1998), and the G/G (Liao et al., 
1998) and A/A (Myllykangas et al., 1999; Pirskanen et al., 2001) genotypes in 
exon 24 of the α2M gene have been reported. Interestingly, the G/G genotype 
in exon 24 of α2M associated with SSA in this study, whereas the genotype 
repeatedly reported to associate with AD in the Finnish population has been 
A/A (Myllykangas et al., 1999; Pirskanen et al., 2001), indicating opposite 
risk factors for SSA and AD. This finding also supports the observed lack 
of association between SSA and AD (III). In the cardiac amyloid deposits, 
α2M protein was not detected. The finding is not conclusive, since IHC 
on a paraffin-embedded tissue may not be able to detect small amounts of 
proteins. However, α2M was found in the myocardial scar tissue, which may 
be due to the activation of extracellular matrix-degrading enzymes after MI 
(Creemers et al., 2001).
In addition, we did not find any association between the α2M gene and 
CAA. In two previous studies, the A/A polymorphism in exon 24 of the 
α2M gene was associated with AD (Myllykangas et al., 1999: Pirskanen et 
al., 2001). Thus, association between CAA and the A/A polymorphism in 
exon 24 was predicted. The lack of association may in part be due to the 
quite small CAA study population. On the other hand, in a previous study 
(Yamada et al., 1999a), no association was detected between CAA and an 
exon 18 polymorphism in the α2M gene.
4.3. Tau gene polymorphisms
In the present study (I), the candidate gene screen showed a significant 
association between SSA and two polymorphisms for the tau gene. The tau 
gene on chromosome 17 is covered by two extended haplotypes in exon 9, 
called H1 and H2, where H1 is the more common haplotype (Baker et al., 
1999). Yet, the region contains a large number of genes that are in linkage 
disequilibrium with tau H1/H2 (Goedert and Jakes, 2005).
Mutations of the tau gene are associated with several neurodegenerative 
diseases (Goedert and Jakes, 2005) including AD. During the years, views on the 
significance of tau in AD  pathogenesis have fluctuated. Studies on association 
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between tau gene polymorphisms and AD have resulted in equivocal results. 
The association of the tau gene with AD pathogenesis is under debate, with 
some studies showing evidence for association (Myers et al., 2005; Goedert 
and Jakes, 2005) and others, including a meta-analysis, showing evidence 
against (Baker et al., 2000; Bullido et al., 2000; Russ et al., 2001; Mukherjee 
et al., 2007) an association. Explanations for the conflicting findings may lie 
in the differences between the populations studied, and secondly, that the tau 
gene region is covered by a large number of genes (Goedert and Jakes, 2005) 
which are in linkage disequilibrium with tau H1/H2. Interestingly, before 
the present finding of association between SSA and tau, tau haplotypes or 
mutations have not been associated with any non-neurological disorder. No 
previous reports exist on genetic association between the tau gene and CAA, 
and in the present study we did not find any association .
4.4. APOE genotypes
Significant association was detected between CAA and the ε4 allele of 
APOE. The association between the severity of CAA and the APOE ε4 allele 
(Polvikoski et al., 1995a), as well as the number of APOE ε4 alleles and severity 
of CAA, has been noted even earlier in slightly younger patients (Chalmers 
et al., 2003). The association between large CAA-related hemorrhages and 
APOE ε2, reported by McCarron and Nicoll (McCarron and Nicoll, 1998), 
was not found here. 
SSA was not associated with APOE polymorphisms, a finding that is in 
line with lack of association between SSA, CAA, dementia, and AD (III).
4.5. ACE, LPL, LRP, and Prion protein polymorphisms
With the exception of α2M, none of the other genetic polymorphisms (i.e. the 
lipid metabolism-, cerebral infarction-, or MI-associated polymorphisms) 
which in previous studies on the same study population associated with 
AD, were associated with SSA. These findings suggest that the pathogenic 
pathways leading to SSA and the above mentioned disorders are unrelated. 
Moreover, the SSA and AD pathologies were not associated with each other 
in the Vantaa study material (III).
In study II, in which the “modified criteria” for AD (Polvikoski et al., 
2001) were used, both clinical and neuropathological AD were associated 
with CAA. Thus, since α2M previously was found to associate with AD 
(Myllykangas et al., 1999), the lack of association between CAA and α2M 
was somewhat unexpected. However, the CAA study population had specific 
features, including lack of association between dementia and the APOE ε 4 
allele, noted even earlier in the Vantaa population (Juva et al., 2000).
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5. IHC FINDINGS IN THE AMYLOID–ASSOCIATED 
AND OTHER PROTEINS
In all amyloids, the IHC showed slightly more wide-ranged positivity 
compared to Congo red. The finding is consistent with the finding in mice 
that TTR amyloid protein has been detected temporally before the amyloid 
fibrils (Teng et al., 2001). The finding of TTR positivity in a few of the Congo 
red- negative (control) myocardial samples may reflect the same idea.
Previously, complement proteins have been detected as associative 
proteins in amyloid deposits in hereditary cerebrovascular ABri and ADan 
amyloidosis (Rostagno et al., 2002). In the present study (II), the co-localized 
complement proteins were highly associated with CAA, and furthermore, 
the amount of complement protein in the amyloidotic blood vessel walls 
increased with the severity of CAA. The complement proteins studied 
here included the terminal component C9, suggesting that complement 
was activated using the classical and alternate pathways as described in 
the chromosome 13 dementias (Rostagno et al., 2002).Here, Aβ and the 
complement proteins C3d and C9 were co-localized with amyloid deposits 
in the amyloidotic blood vessel walls (II). The possibility of nonspecific 
adherence between these proteins exists, but is minor as both Aβ and 
complement perform important functions in the brain tissue. The issue of 
complement, AD, CAA, and Aβ elimination is discussed in detail in the 
Discussion (Chapter 6.4).
AGel deposition is known to be accompanied by ApoE (Soto et al., 1995), 
antichymotrypsin (Kiuru et al., 1999), amyloid P component (Kiuru-Enari et 
al., 2005), and heparin derivatives (Suk et al., 2006). In the present study (IV), 
complement proteins co-localized with variant gelsolin in the degenerated 
nerve structures of the patient with AGel amyloidosis. In hereditary TTR 
amyloidosis, genetic variants of complement 3 and 4 (C3 and C4) have been 
suggested to guide phenotypic diversity (Nylander et al., 1990). The role of 
complement proteins in AGel amyloidosis-associated neurodegeneration is 
not clear. They may represent a reaction in the tissue towards the abnormal 
variant gelsolin protein because in the degenerated posterior columns, where 
no amyloid deposition was noted, complement was also not detectable.
Genetic variation in α2M is strongly and independently associated with SSA 
(see Results, Chapter 4.1.). Thus, the protein itself may accompany amyloid 
material in the myocardial tissue in SSA, although α2M protein was not found 
in the myocardial amyloid deposits. However, this finding is not conclusive 
because small amounts of protein may not be detectable in paraffin-embedded 
tissue material. In contrast, α2M protein was found in myocardial scar tissue. 
This might be explained by activation of the extracellular matrix-degrading 
enzymes after MI (Creemers et al., 2001). α2M protein is a constituent of 
senile plaques in AD (Rebeck et al., 1995), but the presence of this protein 
within CAA deposits was not specifically studied here.
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Phosporylated tau is the constituent of the neurofibrillar tangles that, in 
addition to senile plaques, represents a pathological hallmark for AD. Due 
to the strong genetic association between SSA and tau (Results, Chapter 
4.1.) in the present study (I), the myocardial samples of 14 individuals 
with moderate or severe SSA were immunohistochemically stained with 
anti-tau and anti-phosphorylated tau. The reaction was negative within 
amyloid deposits as well as around them, in the scar tissue and muscle 
fibers. As with α2M, this finding may be not conclusive, because IHC on 
paraffin-embedded tisssue may not detect small amounts of protein. It is 
worth noting that apart from brain tissue in neurodegenerative disorders, 
phosphorylated tau protein has previously been found in muscle tissue in 
inclusion body myositis (Askanas et al., 1994).
Here, the occurrence of AMed amyloidosis in intracranial blood vessels 
was immunohistochemically studied. The lactadherin fragments in the 
leptomeningeal small and middle-sized blood vessels did not co-localize with 
the Aβ–related amyloid deposits, but were located in the blood vessel walls 
outside of the amyloid deposits. The lack of co-localization was confirmed 
by performing a double staining with Congo red and lactadherin fragments 
on a case with advanced CAA. Indeed, in all types of amyloid studied until 
now, only one amyloid fibril protein has been encountered. 
6. EFFECTS OF MULTIPLE FACTORS ON SSA  
AND CAA
6.1. Multivariate analysis of age, α2M and tau gene 
polymorphisms, and MIs on SSA
The Chi-squared test showed a trend for association between MIs and SSA 
(see Results, Chapter 3.6.1.), analogous with a previous hospital-based study 
(Cornwell et al., 1983). After standardizing for confounding factors, the 
logistic regression analysis revealed an independent association between 
these two conditions. Increased HW at autopsy, a common observation 
in various myocardial diseases, was also associated with SSA (see Results, 
Chapter 3.6.1.). Thus, the findings indicate that SSA is often combined with 
other myocardial pathologies, which may be one of the reasons why SSA is 
so seldom clinically diagnosed.
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6.2. Dementia, APOE, and CAA 
CAA was associated with clinical dementia (see Results, Chapter 3.4.2.), and 
APOE ε4 (see Results, Chapter 4.2.). However, clinical dementia was not 
associated, within the power limits of the study, with the presence of ApoE 
ε4 in this study population (see Results, Chapter 6.2.; Juva et al., 2000), in 
contrast with several other studies. This lack of association may be a power 
problem, since a trend towards increased severity of CAA and increased 
frequency of ε4 was seen in the demented subjects compared to nondemented 
subjects. Remarkably, the demented group included not only the AD subjects 
but also vascular and other dementias as well, and CAA was associated with 
dementia in both groups with and without NIA-RI AD (Results, Chapter 
6.2.). All of these results suggest that CAA is not a secondary phenomenon 
associated with AD, but is independently associated with clinical dementia 
in this age group. This finding, combined with the remarkable obliteration 
of the affected vessels in CAA in the histological samples, clearly supports 
the prevailing theory on the origin of AD. This “amyloid cascade hypothesis” 
by Hardy and Selkoe suggests that accumulation of amyloid β-peptide in the 
brain is the key event in the development of AD, but that the rest of the disease 
process including formation of neurofibrillar tangles containing tau protein, 
results from imbalance between the production and clearance of Aβ (Hardy 
and Allsop, 1991; Hardy and Selkoe, 2002). However, even in the 1990s, 
Jack de la Torre brought out the animal model-based theory, that dementia 
is caused by impaired brain perfusion (de la Torre and Fortin, 1994; de la 
Torre, 1997; de la Torre and Stefano, 2000). The possibility of a primary role 
of the CNS vascular system in AD pathogenesis in humans is also supported 
by Zlokovic et al., who suggested that alterations in the transport across the 
BBB may have a substantial role in the development of cerebral β-amyloidosis 
in AD (Zlokovic, 2002; Zlokovic, 2004). It has even been suggested that 
the soluble forms of Aβ may be in response of many of its neurotoxic and 
vasculotoxic effects, thus representing a potential link between AD and 
vascular mechanisms of dementia (Zlokovic, 2005). Dermaut has suggested 
that CAA may represent a pathogenic lesion with significant contribution 
to progressive neurodegeneration in AD (Dermaut et al., 2001), based on 
investigations of a family with an early-onset novel presenilin-1 mutation 
(L282V)-associated AD. A scheme for AD pathogenesis in which ischemia 
plays a crucial role in influencing and linking β-amyloid deposition to 
neuronal damage and clinical disease has recently been presented by Pluta 
(Pluta, 2004). Other pathogenic pathways for AD development include 
oxidative stress and mitogenic dysregulation, which are even thought to 
cause other neurodegenerative diseases (Zhu et al., 2007) and mitochondrial 
dysfunction (Chen et al., 2006).
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6.3. Clinical dementia, CAA, and SSA
CAA associated with clinical dementia in both the SSA+ and SSA- groups 
(see Results, Chapter 6.3.). This finding further strengthens the independency 
of association between CAA and clinical dementia, an association that is 
also independent of SSA.
6.4. Complement, AD, CAA, and Aβ elimination
In AD, complement is a part of the inflammatory cascade in senile 
plaques, triggered by Aβ as described earlier (Akiyama et al., 2000). Other 
complement-activating factors in the brain include infarction (Lindsberg et 
al., 1996), hemorrhage, infection, and possibly even a sustained breach in the 
BBB (Bradt et al., 1998). In the present study, acute or old ischemic lesions 
or hemorrhages were encountered only in a subset of cases, suggesting that 
complement activation in CAA is probably not explained by hypoxic stress. 
In fact, cases with small cortical infarcts showed somewhat less complement 
activity, perhaps due to increasing tissue clearance associated with scarring 
of the infarction. The study also revealed a lack of association between iron 
and complement deposition, suggesting that complement-mediated lysis of 
cell- or basal membranes was not present or did not cause ongoing blood 
extravasation. Both of these findings suggest that in these very old subjects 
neither ischemia nor blood extravasation activates complement. Thus, Aβ 
should be considered as a respectable candidate as a trigger of complement 
activation in these very elderly individuals. Apart from being a part of the 
inflammatory reactions, complement also has a role in assisting with the 
removal of targeted molecules (Rogers et al., 2002). Thus, complement might 
be associated with failure in eliminating Aβ, which is proposed to result in 
CAA (Feurer and Weller, 1991; McLean et al., 1999). In vitro experiments 
show that Aβ 1-40 is cleared from young murine brains via the endothelium 
into the blood, mediated by low density lipoprotein (LDL) receptor related 
protein–1 (LRP-1), α2-macroglobulin, and possibly also ApoE (Ghersi-Egea 
et al., 1996; Shibata et al., 2000). A clearance by this route directly into the 
blood is reduced in older mice, in whom perivascular pathways seem to 
be more significant (Shibata et al., 2000). Recently, the perivascular route 
of Aβ elimination from the extracellular spaces of the human brain along 
the walls of capillaries, as well as cortical and leptomeningeal arteries, has 
recently been defined (Preston et al., 2003).
It has been shown that Aβ is able to activate complement by binding to 
C1Q in an antibody-independent fashion (Rogers et al., 2002; Bradt et al., 
1998). Although C1Q was not investigated in the present study (II), co-
localization of complement proteins (C3d and C9) with amyloidotic blood 
vessels in CAA may be representative of this binding. Interestingly, only the 
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smallest vascular amyloid deposits were devoid of complement proteins. 
This may imply that there must be sufficient Aβ to activate complement. 
However, the involvement of complement proteins in the complex course 
of Aβ elimination and subsequent development of CAA requires further 
investigation.
7. THE STRENGTHS AND LIMITATIONS OF  
THE STUDY 
The strength of the Vantaa 85+ study is that it is prospective and population-
based, thus lacking selection bias often involved in epidemiological studies. 
The study is powerful because the Finnish population is based on a small 
number of founders, and therefore the number of genetic risk factors for 
diseases may be smaller than in other populations. The autopsy rate of the 
Vantaa 85+ study, 51%, is the second highest among all population-based 
neuropathological autopsy studies with only the Japanese Hisayma study 
exeeding this rate (Zaccai et al., 2006). Although the autopsy frequencies in 
both the SSA and CAA studies were somewhat lower, the results are reliable, 
especially as the diagnosis of both SSA and CAA cannot be made without 
a histological sample.
On the other hand, due to the special nature of the Finnish population, the 
results may thus be limited to this population only. In addition, the number 
of subjects in the study population is relatively small, and thus the possibility 
of false positive results cannot be totally excluded, albeit the population was 
very carefully characterized. Finally, the utility of SNP-based association 
studies for complex human diseases has become an increasingly debated 
question (Fallin et al., 2001). In the future, ultramodern techniques using 
high-density whole-genome association approaches (Coon et al., 2007) may 
prove to be more informative in studies on multigenic diseases.
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CONCLUSION
This population-based study shows that SSA and CAA are not associated with 
each other, but either or both of them are detected in two-thirds of very elderly 
individuals. Old age, myocardial infarctions, exon 24 polymorphisms of the 
α-2M gene, and the H1/H2 polymorphism of the tau gene is associated with 
SSA, while clinical dementia and APOE ε4 genotype is associated with CAA. 
A strong association between CAA and clinical dementia was demonstrated, 
which was independent of APOE ε4 genotype and neuropathological AD. 
This highlights the clinical significance of CAA in very elderly individuals, 
in whom serious end-stage complications of CAA (e.g. multiple infarctions 
and hemorrhages) are seldom. Further, complement 3d and 9 were present 
in amyloid deposits in CAA and AGel amyloidosis, and advanced AGel 
amyloidosis was shown to be fatal. Due to the high prevalence of SSA in 
the elderly population, prospective clinical studies are needed to define its 
clinical significance.
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